Data / Research funding / Liver Disease
Liver Disease: 3,000 NIH awards ($4.2B) to 473 organizations
3,000 NIH awards ($4.2B) in the NIH spending category Liver Disease, to 473 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 3,000 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $472,070,715 | December 1, 2024 | November 30, 2025 | CURRIER, JUDITH S. | reporter.nih.gov |
| AIDS Clinical Trial Group Laboratory Center | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $56,714,107 | January 1, 2014 | November 30, 2027 | ALDROVANDI, GRACE M | reporter.nih.gov |
| Epidemiology of Diabetes Interventions and Complications (EDIC) Study | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $35,015,476 | September 22, 2011 | June 30, 2027 | GUBITOSI-KLUG, ROSE A | reporter.nih.gov |
| University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $24,477,809 | February 1, 2007 | November 30, 2027 | ERON, JOSEPH J | reporter.nih.gov |
| UCLA AIDS Prevention and Treatment Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,546,764 | February 1, 2007 | November 30, 2027 | LANDOVITZ, RAPHAEL J | reporter.nih.gov |
| Boston HIV CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,445,869 | January 15, 2007 | November 30, 2027 | KURITZKES, DANIEL R. | reporter.nih.gov |
| University of Arizona Cancer Center - Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $21,155,920 | July 1, 1997 | July 31, 2027 | THEODORESCU, DAN | reporter.nih.gov |
| Expanding HOPE Liver Transplantation: Understanding Opportunistic Infection and Cancer Risk | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $18,807,472 | August 1, 2018 | August 31, 2030 | DURAND, CHRISTINE MARIE | reporter.nih.gov |
| NIAID VIROLOGY QUALITY ASSURANCE (VQA) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $17,732,468 | June 21, 2025 | June 20, 2026 | DENNY, THOMAS | reporter.nih.gov |
| Guide RNA manufacturing capabilities for platform in vivo base editing therapies for metabolic liver diseases | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $17,556,074 | August 1, 2023 | July 31, 2028 | PERANTEAU, WILLIAM H. | reporter.nih.gov |
| International epidemiology Databases to Evaluate AIDS (IeDEA) Southern Africa. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,840,939 | May 1, 2025 | April 30, 2027 | ROHNER, ELIANE | reporter.nih.gov |
| Center for Cellular Metabolism Research in Oklahoma | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $15,159,612 | February 5, 2021 | January 31, 2027 | XIA, LIJUN | reporter.nih.gov |
| Pediatric Acute Liver Failure Immune Response Network (PALF IRN): Treatment for Immune Mediated Pathophysiology (TRIUMPH) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $13,418,019 | June 15, 2021 | May 31, 2027 | ALONSO, ESTELLA M. | reporter.nih.gov |
| Pitt-Ohio State Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,065,770 | February 1, 2007 | November 30, 2027 | RIDDLER, SHARON | reporter.nih.gov |
| Hepatobiology and Toxicology COBRE | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $12,863,981 | June 10, 2016 | March 31, 2027 | MCCLAIN, CRAIG J. | reporter.nih.gov |
| Vanderbilt HIV Clinical Trials Unit (CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,733,650 | February 1, 2007 | November 30, 2027 | HAAS, DAVID W | reporter.nih.gov |
| CURE CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,461,433 | January 1, 2007 | November 30, 2027 | SPECTOR, STEPHEN A | reporter.nih.gov |
| AIDS Linked to the IntraVenous Experience (ALIVE) Study | NIH | National Institute on Drug Abuse | 2021 to 2025 | $12,226,379 | January 1, 2014 | May 31, 2030 | MEHTA, SHRUTI H | reporter.nih.gov |
| COBRE in Digestive and Liver Disease | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $11,909,573 | April 3, 2020 | June 30, 2030 | DUNCAN, STEPHEN A | reporter.nih.gov |
| Durable Alteration of the Human Immune system after Infection or Immunotherapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,785,761 | June 8, 2009 | May 31, 2029 | CHUNG, RAYMOND T | reporter.nih.gov |
| Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD) - Indiana University Data Coordinating Center | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $11,773,646 | August 1, 2018 | June 30, 2029 | TU, WANZHU | reporter.nih.gov |
| Center for Pre-Clinical Cancer Research | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $11,277,290 | March 1, 2021 | February 28, 2027 | FRANCIS, JOSEPH | reporter.nih.gov |
| Mays Cancer Center at UT Health SA | NIH | National Cancer Institute | 2021 to 2025 | $11,193,809 | August 1, 1997 | July 31, 2026 | ZHENG, LEI | reporter.nih.gov |
| Utility of Biomarkers of Rejection and Kidney Injury in Tailoring Liver Transplant Immunosuppression | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,920,671 | September 6, 2021 | June 30, 2028 | BOIKE, JUSTIN | reporter.nih.gov |
| Reagent Program for HIV and other Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,735,388 | October 15, 2023 | January 13, 2024 | RASHID, SUJATHA | reporter.nih.gov |
| Liver Cirrhosis Network: Scientific and Data Coordination Center | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $10,655,826 | August 28, 2021 | July 31, 2027 | SMITH, ABIGAIL | reporter.nih.gov |
| Addressing risk through Community Treatment for Infectious disease and Opioid use disorder Now (ACTION) among justice-involved populations | NIH | National Institute on Drug Abuse | 2021 to 2025 | $10,550,278 | September 30, 2020 | July 31, 2026 | SPRINGER, SANDRA ANN | reporter.nih.gov |
| Kansas Center for Metabolism and Obesity REsearch (KC-MORE) | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $10,233,525 | April 1, 2022 | February 28, 2027 | WEINMAN, STEVEN A | reporter.nih.gov |
| Thailand HIV/AIDS and Infectious Disease Clinical Trials Unit (THAI CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,070,868 | March 15, 2007 | November 30, 2027 | SUPPARATPINYO, KHUANCHAI | reporter.nih.gov |
| Southern Liver Health Cohort | NIH | National Cancer Institute | 2023 to 2025 | $10,038,112 | September 21, 2021 | August 31, 2027 | HOYO, CATHRINE | reporter.nih.gov |
| The Johns Hopkins University - Uganda Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,910,249 | February 5, 2007 | November 30, 2027 | FOWLER, MARY GLENN | reporter.nih.gov |
| Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant candidates (COLT) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $9,640,870 | August 26, 2021 | September 30, 2024 | LIMAYE, ABHIJIT PRAKASH | reporter.nih.gov |
| Childhood Liver Disease Research Network (ChiLDReN) Scientific and Data Coordinating Center | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $9,404,513 | September 18, 2002 | May 31, 2029 | MAGEE, JOHN C | reporter.nih.gov |
| Health Economics of Substance Use Disorder, HCV, and HIV Treatment: Supporting Financial Sustainability, Advanced Methods, and Knowledge Translation | NIH | National Institute on Drug Abuse | 2021 to 2025 | $8,690,640 | July 15, 2015 | April 30, 2030 | SCHACKMAN, BRUCE R | reporter.nih.gov |
| Data Coordinating Center for the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Continuation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $8,663,508 | May 1, 2002 | June 30, 2028 | SHADE, DAVID M | reporter.nih.gov |
| The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,239,326 | January 15, 2008 | November 30, 2027 | GRINSZTEJN, BEATRIZ | reporter.nih.gov |
| Columbia Diabetes Research Center | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $7,800,557 | September 1, 2002 | December 31, 2027 | PAJVANI, UTPAL | reporter.nih.gov |
| A trial of transplanting Hepatitis C-viremic kidneys into Hepatitis C-Negative kidney recipients (THINKER-NEXT) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $7,767,541 | April 15, 2021 | March 31, 2027 | SCHAUBEL, DOUGLAS EARL | reporter.nih.gov |
| Personalized prime editing as a platform for hepatic inborn errors of metabolism | NIH | National Center for Advancing Translational Sciences | 2024 to 2025 | $6,886,793 | September 20, 2024 | August 31, 2028 | AHRENS-NICKLAS, REBECCA CLARE | reporter.nih.gov |
| Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism | NIH | National Institute on Drug Abuse | 2021 to 2024 | $6,868,774 | April 1, 2020 | January 31, 2026 | STRATHDEE, STEFFANIE A. | reporter.nih.gov |
| Subcutaneous Drug Development for Portal Hypertension Ascites | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $6,758,500 | September 22, 2014 | July 31, 2027 | CASTILLO, GERARDO M. | reporter.nih.gov |
| Novel therapy for alcoholic liver disease-associated hepatorenal syndrome | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $6,485,223 | September 25, 2021 | August 31, 2027 | SUBRAMANIAN, MANI | reporter.nih.gov |
| Yale Liver Center | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $6,469,647 | September 30, 1997 | June 16, 2026 | NATHANSON, MICHAEL H | reporter.nih.gov |
| Decoding mechanisms underlying metabolic dysregulation in obesity and digestive cancer risk | NIH | National Cancer Institute | 2022 to 2025 | $6,443,697 | September 20, 2022 | August 31, 2027 | TOBIAS, DEIRDRE KAY | reporter.nih.gov |
| The Cleveland Digestive Diseases Research Core Center (DDRCC) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $6,425,666 | February 15, 2015 | August 31, 2030 | COMINELLI, FABIO | reporter.nih.gov |
| The spectrum of cognitive impairment including Alzheimer’s Disease and Related Dementias after liver transplantation | NIH | National Institute on Aging | 2021 to 2025 | $6,330,805 | June 15, 2018 | May 31, 2028 | LAI, JENNIFER C. | reporter.nih.gov |
| Biologically informed design of CD8+ T cell-dependent pre-erythrocytic stage malaria vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,330,175 | February 4, 2021 | January 31, 2026 | KAPPE, STEFAN HI | reporter.nih.gov |
| The HIV and Alcohol Research center focused on Polypharmacy (HARP) | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $6,323,238 | September 10, 2021 | August 31, 2026 | JUSTICE, AMY CAROLINE | reporter.nih.gov |
| Pittsburgh Liver Research Center | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $6,209,773 | July 1, 2019 | March 31, 2029 | MONGA, SATDARSHAN SINGH | reporter.nih.gov |
| Ancillary Studies of NAFLD and NASH in HIV infected Adults | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $6,132,391 | March 21, 2020 | January 31, 2026 | CHALASANI, NAGA P | reporter.nih.gov |
| Johns Hopkins HIV Clinical Cohort | NIH | National Institute on Drug Abuse | 2021 to 2024 | $5,955,256 | July 1, 2014 | March 31, 2026 | MOORE, RICHARD DOUGLAS | reporter.nih.gov |
| Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant candidates (COLT) | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $5,882,740 | August 26, 2021 | May 31, 2028 | LIMAYE, ABHIJIT PRAKASH | reporter.nih.gov |
| Rational design and efficacy testing of vaccines against HCV | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,737,237 | May 5, 2022 | April 30, 2027 | FUERST, THOMAS R | reporter.nih.gov |
| Histidine phosphorylation as a new target for cancer therapy | NIH | National Cancer Institute | 2021 to 2025 | $5,690,698 | September 18, 2019 | August 31, 2026 | HUNTER, TONY R. | reporter.nih.gov |
| Improvements to the Regional Biocontainment Research Facilities at the University of Missouri | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $5,667,997 | September 23, 2021 | February 28, 2025 | LORSON, CHRISTIAN L. | reporter.nih.gov |
| MUSC Digestive Disease Research Core Center | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $5,554,374 | April 15, 2020 | August 31, 2030 | ROCKEY, DON C. | reporter.nih.gov |
| Effects of Intermittent Energy Restriction on Intra-Abdominal Fat and the Gut Microbiome: A Randomized Trial | NIH | National Cancer Institute | 2021 to 2025 | $5,478,236 | September 22, 2021 | August 31, 2026 | LE MARCHAND, LOIC | reporter.nih.gov |
| Chicago Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,330,849 | February 1, 2007 | November 30, 2027 | ACHENBACH, CHAD J | reporter.nih.gov |
| A Randomized Controlled Trial of Prophylaxis with Direct-acting Antivirals for Kidney Transplantation from Hepatitis C virus-infected donor to Uninfected Recipients (PREVENT-HCV) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,162,956 | March 25, 2022 | February 28, 2027 | DURAND, CHRISTINE MARIE | reporter.nih.gov |
| High-throughput proteomics using submicroliter amounts of plasma for comprehensive assessment of the immune status | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,147,391 | April 9, 2020 | March 31, 2026 | STEEN, HANNO | reporter.nih.gov |
| Drug Induced Liver Injury Network Data Coordinating Center | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $5,081,421 | September 30, 2003 | July 31, 2028 | BARNHART, HUIMAN X | reporter.nih.gov |
| Targeting the MYC Pathway for the Treatment of Cancer | NIH | National Cancer Institute | 2021 to 2025 | $4,931,456 | September 8, 2020 | August 31, 2027 | FELSHER, DEAN W | reporter.nih.gov |
| Establishing patient-derived iPSCs as a platform for discovery research in NAFLD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $4,780,391 | June 1, 2023 | March 31, 2028 | MAHER, JACQUELYN J. | reporter.nih.gov |
| Metabolic Influences on Complex Tumor Neighborhoods | NIH | National Cancer Institute | 2021 to 2025 | $4,722,150 | August 1, 2017 | July 31, 2030 | SIMON, M. CELESTE | reporter.nih.gov |
| Development of Non-Human Primate Models to Assess Immunological Mechanisms and Antigenic Targets of Protective Sporozoite (SPZ) Vaccines and Establish Superior Efficacy of Next Generation SPZ vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,717,265 | April 1, 2021 | March 31, 2027 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Targeting hepatic stellate cell metabolism to treat steatotic liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $4,674,973 | April 1, 2015 | August 31, 2029 | FINCK, BRIAN N | reporter.nih.gov |
| Integrating Addiction and Infectious Diseases Services into Primary Care in Rural Settings | NIH | National Institute on Drug Abuse | 2021 to 2025 | $4,664,222 | August 1, 2021 | May 31, 2027 | ALTICE, FREDERICK LEWIS | reporter.nih.gov |
| Live-cell Activity Architecture in Cancer | NIH | National Cancer Institute | 2021 to 2025 | $4,655,641 | August 1, 2015 | July 31, 2029 | ZHANG, JIN | reporter.nih.gov |
| Non-alcoholic Fatty Liver Disease and Cardiovascular Disease in Hispanics/Latinos | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $4,589,716 | September 1, 2019 | August 31, 2024 | KIZER, JORGE R | reporter.nih.gov |
| Microphysiological systems to interrogate the Islet-Liver-Adipose Axis in normal physiology and Type-2 Diabetes Mellitus | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $4,582,323 | September 20, 2018 | July 31, 2024 | STAHL, ANDREAS | reporter.nih.gov |
| Increasing Access to Hepatitis C Treatment in Opioid Endemic Rural Areas: the Kentucky Viral Hepatitis Treatment (KeY Treat) Study | NIH | National Institute on Drug Abuse | 2021 to 2023 | $4,371,481 | September 30, 2018 | July 31, 2025 | HAVENS, JENNIFER R | reporter.nih.gov |
| Human Microphysiology Systems Disease Model of Type 2 Diabetes Starting with Liver and pancreatic Islets | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $4,324,679 | September 20, 2018 | July 31, 2023 | TAYLOR, D. LANSING | reporter.nih.gov |
| Porphyrias Consortium | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $4,280,404 | September 30, 2009 | June 30, 2025 | DESNICK, ROBERT J | reporter.nih.gov |
| Live cell reporters of genetic changes in stiff vs soft surroundings - Causes & Consequences | NIH | National Cancer Institute | 2021 to 2025 | $4,251,467 | April 1, 2021 | March 31, 2026 | DISCHER, DENNIS E. | reporter.nih.gov |
| Xenobiotic Receptors in Mediating the Environmental Effects on Human Disease and Morbidity | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $4,237,518 | August 1, 2019 | May 31, 2027 | XIE, WEN | reporter.nih.gov |
| The Long-Acting/Extended Release Antiretroviral Resource Program (LEAP) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,204,220 | May 15, 2015 | June 30, 2030 | FLEXNER, CHARLES W. | reporter.nih.gov |
| Integrating HCV services into HIV programs for PWID in India | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,184,487 | July 8, 2019 | June 30, 2025 | MEHTA, SHRUTI H | reporter.nih.gov |
| Development of an oral liver-targeted prime-and-trap malaria vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,104,491 | December 1, 2020 | November 30, 2026 | MURPHY, SEAN C | reporter.nih.gov |
| Altered metabolism and machine learning for pancreatic cancer early detection | NIH | National Cancer Institute | 2021 to 2025 | $4,100,528 | September 16, 2022 | August 31, 2027 | WOLPIN, BRIAN MATTHEW | reporter.nih.gov |
| RADx Innovation Funnel for Hepatitis B Diagnostics - Coordination Center | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $4,074,004 | September 30, 2024 | September 29, 2026 | SCHACHTER, STEVEN C. | reporter.nih.gov |
| A novel diagnostic Kit for Hepatocellular Carcinoma | NIH | National Cancer Institute | 2021 to 2023 | $3,993,675 | September 1, 2012 | August 31, 2025 | LU, XUANYONG | reporter.nih.gov |
| A systems immunology approach for predicting poor responses to Hepatitis B vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,925,255 | September 17, 2021 | August 31, 2026 | HERATI, RAMIN | reporter.nih.gov |
| Next-generation human liver gene therapy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,896,814 | September 30, 2021 | June 30, 2027 | WILLENBRING, HOLGER | reporter.nih.gov |
| Making Better Decisions: Policy Modeling for AIDS and Drug Abuse | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,865,844 | September 25, 2022 | January 31, 2029 | OWENS, DOUGLAS K | reporter.nih.gov |
| Precision Risk Stratification and Screening for HCC among Patients with Indeterminate Liver Nodules | NIH | National Cancer Institute | 2023 to 2025 | $3,858,633 | September 19, 2023 | August 31, 2028 | SINGAL, AMIT | reporter.nih.gov |
| A Rhesus Macaque Model of HIV and HBV co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,842,980 | March 20, 2021 | February 28, 2026 | BURWITZ, BENJAMIN J | reporter.nih.gov |
| The UCLA Center in Early Detection of Liver Cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,825,539 | September 17, 2018 | August 31, 2028 | ZHOU, XIANGHONG JASMINE | reporter.nih.gov |
| Spatio-temporal Methods for Surveillance of the Opioid Syndemic | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,748,657 | September 1, 2025 | August 31, 2029 | KLINE, DAVID M | reporter.nih.gov |
| Clinical Validation Center for Hepatocellular Carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $3,730,583 | August 3, 2022 | July 31, 2027 | SINGAL, AMIT | reporter.nih.gov |
| Pathogenesis of youth onset pre-diabetes and Type 2 diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,716,431 | September 22, 2016 | July 31, 2026 | CAPRIO, SONIA | reporter.nih.gov |
| HAWAII CLINICAL RESEARCH NETWORK FOR HEALTH EQUITY | NIH | National Institute on Minority Health and Health Disparities | 2024 to 2025 | $3,711,764 | September 24, 2022 | November 30, 2027 | SHIKUMA, CECILIA M. | reporter.nih.gov |
| Identification and Characterization of Entry Factors Critical for Rift Valley Fever Virus Infection and Pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,704,381 | March 19, 2021 | February 28, 2027 | AMARASINGHE, GAYA K. | reporter.nih.gov |
| Conduct Synthesis and Acquire Batches of Compounds for Subsequent Biological In Vitro and In Vivo Testing | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,702,250 | April 1, 2024 | March 31, 2025 | MIDDLETON, MARK | reporter.nih.gov |
| Restoring Central Regulation of Glucose Production in Type 2 Diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,695,446 | June 15, 2006 | April 30, 2027 | HAWKINS, MEREDITH A | reporter.nih.gov |
| Novel Determinants for Progression of Non-Alcoholic Fatty Liver Disease to Hepatocellular Carcinoma and Other Health Outcomes | NIH | National Cancer Institute | 2021 to 2025 | $3,678,371 | September 7, 2021 | August 31, 2026 | YUAN, JIAN-MIN | reporter.nih.gov |
| Enhancing immune regulation in gene therapy for hemophilia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,664,714 | July 1, 2016 | June 30, 2029 | HERZOG, ROLAND W. | reporter.nih.gov |
| Trial of Statins for Chemoprevention in Hepatocellular Carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $3,646,155 | September 1, 2021 | August 31, 2027 | CHUNG, RAYMOND T | reporter.nih.gov |
| Estrogen Administration for the Treatment of NASH in Postmenopausal Women | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,638,994 | August 1, 2021 | May 31, 2027 | MILLER, KAREN K | reporter.nih.gov |
| Clinical & Immunological Study of Treatment Withdrawal in E-Ag Negative Hepatitis B | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,618,437 | September 1, 2016 | June 30, 2026 | COOPER, STEWART | reporter.nih.gov |
| NIH: Spatial Models of Intrahepatic Hepatitis Virus Propagation in Humans | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,593,236 | February 7, 2022 | January 31, 2027 | RIBEIRO, RUY M | reporter.nih.gov |
| Assessing the effects of oral pre-exposure prophylaxis on pharmacokinetics of monoclonal and vaccine-induced antibodies among women vulnerable to HIV-1 | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,554,273 | September 12, 2025 | August 31, 2029 | HUANG, YUNDA | reporter.nih.gov |
| Interactions between neutrophils and cholangiocytes in alcoholic hepatitis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $3,548,231 | September 25, 2021 | June 30, 2027 | NATHANSON, MICHAEL H | reporter.nih.gov |
| Risk Stratification for and Early Detection of Liver Cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,531,567 | September 13, 2018 | August 31, 2028 | KANWAL, FASIHA | reporter.nih.gov |
| Impact of the COVID-19 pandemic on patient outcomes, telehealth care delivery, and treatment for unhealthy alcohol use in vulnerable patients with advanced liver disease across two healthcare systems | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $3,517,747 | June 1, 2021 | February 28, 2027 | KHALILI, MANDANA | reporter.nih.gov |
| Acute/chronic limitations to transcriptional RNAi therapies for infectious and other liver diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,515,317 | August 1, 2006 | July 31, 2026 | KAY, MARK A | reporter.nih.gov |
| Structural and Mechanistic basis for RNA Silencing | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,507,599 | August 1, 2018 | July 31, 2028 | MACRAE, IAN JOHN | reporter.nih.gov |
| Clinical Center for Cholestatic Liver Disease in Children | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,505,921 | September 15, 2002 | May 31, 2029 | MIETHKE, ALEXANDER | reporter.nih.gov |
| Abbreviated MRI for HCC screening in cirrhotic patients | NIH | National Cancer Institute | 2021 to 2024 | $3,461,079 | June 19, 2020 | May 31, 2026 | TAOULI, BACHIR | reporter.nih.gov |
| AcetaSTAT Validation and Commercialization | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $3,458,961 | April 1, 2008 | March 31, 2026 | JAMES, LAURA P | reporter.nih.gov |
| A Phase 1-2 clinical program for the teatment of Microsatellite Stable Colorectal Cancer with the combination of SR-8541A, Botensilimab, and Balstilimab | NIH | National Cancer Institute | 2022 to 2025 | $3,457,194 | August 14, 2025 | July 31, 2028 | KAADIGE, MOHAN RAO | reporter.nih.gov |
| Clinical Research on Nonalcoholic Fatty Liver Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,430,513 | September 15, 2002 | June 30, 2027 | LOOMBA, ROHIT | reporter.nih.gov |
| Training in Pediatric Gastroenterology, Hepatology, and Nutrition | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,415,797 | December 1, 1983 | April 30, 2029 | SNAPPER, SCOTT B | reporter.nih.gov |
| Human Genetic determinants of HBV recovery | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,412,348 | September 30, 1999 | December 31, 2026 | THOMAS, DAVID L | reporter.nih.gov |
| Combating Related Epidemics in HCV through Simplified Testing and Treatment (CREST) | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,411,692 | September 24, 2025 | August 31, 2030 | NAGGIE, SUSANNA | reporter.nih.gov |
| Uncovering the parasite and host determinants of Plasmodium vivax hypnozoite formation and development using single cell sequencing and human liver-chimeric mice | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,399,010 | February 7, 2022 | January 31, 2027 | VAUGHAN, ASHLEY M | reporter.nih.gov |
| Evaluation of a community-based education, navigation, and support (CENS) intervention to reduce opioid-related harms among military veterans | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,379,762 | September 30, 2021 | July 31, 2027 | BENNETT, ALEXANDER S | reporter.nih.gov |
| AN INTEGRATED PLATFORM FOR NOVEL PERSONALIZED LIVER CANCER THERAPEUTICS | NIH | National Cancer Institute | 2021 to 2025 | $3,349,717 | July 1, 2021 | June 30, 2027 | GUCCIONE, ERNESTO | reporter.nih.gov |
| Promoting remote and secondary risk prevention services in rural settings | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,349,340 | September 30, 2022 | July 31, 2027 | PHO, MAI TUYET | reporter.nih.gov |
| Role of ABCG1, ABCG5 and ABCG8 in Sterol Metabolism | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,341,148 | February 1, 2003 | November 30, 2025 | HOBBS, HELEN HASKELL | reporter.nih.gov |
| Liquid biopsy and radiomics for liver cancer surveillance | NIH | National Cancer Institute | 2023 to 2025 | $3,338,250 | September 19, 2023 | August 31, 2028 | TAOULI, BACHIR | reporter.nih.gov |
| Immunologic correlates of functional cure of HBV with immune checkpoint blockade | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,338,136 | May 22, 2020 | April 30, 2026 | LAUER, GEORG MICHAEL | reporter.nih.gov |
| "A microbiome-dependent bile acid metabolite improves type 2 diabetes." | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,304,418 | January 8, 2021 | December 31, 2026 | SHEU, ERIC GARLAND | reporter.nih.gov |
| A geospatial analysis of hotspots and targeted injection settings pilot intervention for HIV prevention among people who inject drugs in Baltimore, Maryland | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,292,995 | July 1, 2020 | May 31, 2027 | LATKIN, CARL A | reporter.nih.gov |
| A smartphone-enabled point-of-care HCV Ag diagnostic using catalytic nanoparticles and AI-enhanced image processing | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $3,284,055 | September 9, 2022 | June 30, 2027 | SHAFIEE, HADI | reporter.nih.gov |
| Prevention of Pediatric NAFLD in Hispanic Children | NIH | National Institute of Nursing Research | 2021 to 2025 | $3,279,874 | April 5, 2021 | January 31, 2026 | WELSH, JEAN A. | reporter.nih.gov |
| Prospective evaluation of outcomes in cirrhosis of different etiologies: impact of HIV infection and simvastatin therapy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,276,651 | September 23, 2021 | July 31, 2027 | DASARATHY, SRINIVASAN | reporter.nih.gov |
| Stable therapy in Pompe disease through genome editing | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $3,274,213 | August 1, 2021 | July 31, 2026 | KOEBERL, DWIGHT D | reporter.nih.gov |
| IL-27R signaling as a negative regulator of innate and adaptive anti-cancer immunity in hepatocellular carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $3,273,154 | August 1, 2022 | July 31, 2027 | KOLTSOVA, EKATERINA | reporter.nih.gov |
| Longitudinal Study of Early NAFLD Progression and the Gut Microbiome in Asian Americans, Native Hawaiians and Whites | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2025 | $3,263,901 | September 26, 2022 | June 30, 2027 | LIM, UNHEE | reporter.nih.gov |
| Liver Cirrhosis Network: Longitudinal and Clinical Trial Studies | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,258,965 | September 6, 2021 | July 31, 2027 | KHALILI, MANDANA | reporter.nih.gov |
| Lead optimization of Hepatitis B Virus ribonuclease H inhibitors | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,253,243 | December 1, 2020 | November 30, 2026 | TAVIS, JOHN E | reporter.nih.gov |
| Implementation of telemedicine and social network driven HIV service uptake for comprehensive HIV service integration in rural syringe service programs | NIH | National Institute on Drug Abuse | 2023 to 2025 | $3,234,132 | August 1, 2023 | May 31, 2028 | FALADE-NWULIA, OLUWASEUN | reporter.nih.gov |
| Role of Neutrophils in the Pathogenesis of Cholangiopathies | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $3,233,421 | September 1, 2025 | August 31, 2029 | STRAZZABOSCO, MARIO | reporter.nih.gov |
| Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasis | NIH | National Cancer Institute | 2021 to 2025 | $3,231,041 | August 9, 2021 | July 31, 2026 | SMALLEY, KEIRAN | reporter.nih.gov |
| Examine Individual and Clinical Factors Affecting Liver Disease Management | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2025 | $3,219,854 | September 15, 2022 | May 31, 2027 | MA, GRACE X. | reporter.nih.gov |
| Extracellular Vesicle-Based Digital Scoring Assay for Detecting Early-stage Hepatocellular Carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $3,197,232 | January 18, 2021 | December 31, 2026 | ZHU, YAZHEN | reporter.nih.gov |
| Immunomodulation in AAV gene therapy | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,192,404 | August 21, 2025 | July 31, 2029 | ASOKAN, ARAVIND | reporter.nih.gov |
| Neutralizing antibody responses during natural control of acute hepatitis B with and without HIV-1 coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,186,484 | August 1, 2022 | July 31, 2027 | BAILEY, JUSTIN RICHARD | reporter.nih.gov |
| Collaborative Integration of HCV Molecular Virology and Mathematical Modeling | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,185,361 | August 1, 2010 | May 31, 2027 | UPRICHARD, SUSAN L. | reporter.nih.gov |
| Intestinal proteases in alcohol-associated liver disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2025 | $3,182,397 | September 20, 2025 | August 31, 2029 | SCHNABL, BERND G. | reporter.nih.gov |
| Novel macrophage mediated signals regulate the immunoregulatory environment of the neonatal liver | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $3,176,680 | September 15, 2025 | September 14, 2029 | NIJAGAL, AMAR | reporter.nih.gov |
| Simultaneous MRI/US for real-time liver ablation guidance and confirmation | NIH | National Cancer Institute | 2022 to 2025 | $3,174,892 | August 15, 2022 | July 31, 2027 | HOLMES, JAMES H | reporter.nih.gov |
| Drug eluting injectable biomaterials for next generation chemoembolization | NIH | National Cancer Institute | 2021 to 2025 | $3,173,416 | May 1, 2021 | April 30, 2027 | OKLU, RAHMI | reporter.nih.gov |
| CTRP and Metabolic Control | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,168,077 | July 15, 2010 | June 30, 2028 | WONG, GUANG WILLIAM | reporter.nih.gov |
| Launching HBV with RNA to assess antiviral resistance and explore fundamental aspects of virus-host biology | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,156,556 | February 10, 2020 | April 30, 2030 | RICE, CHARLES M | reporter.nih.gov |
| Extracellular vesicle cargo and risk of NAFLD and NASH in U.S. youth | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $3,153,279 | April 15, 2022 | February 28, 2027 | DISTEFANO, JOHANNA K | reporter.nih.gov |
| Impact of harm reduction care in HIV clinical settings on stigma and health outcomes for PLWH who use drugs | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,152,106 | September 30, 2021 | June 30, 2027 | HAWK, MARY ELIZABETH | reporter.nih.gov |
| New Generation of Mitochondrial Uncouplers for the Treatment of Metabolic DIsorders | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $3,142,274 | September 20, 2021 | June 30, 2026 | VU, SIMON | reporter.nih.gov |
| Molecular and structural characterization of broadly neutralizing anti-HCV antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,115,747 | February 15, 2023 | January 31, 2028 | BAILEY, JUSTIN RICHARD | reporter.nih.gov |
| Epigenetics of human Hepatic Stellate Cells (HSCs) in NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,103,795 | May 15, 2014 | August 31, 2027 | KISSELEVA, TATIANA | reporter.nih.gov |
| Modeling diabetes using an integrated plate system | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $3,092,998 | September 20, 2018 | July 31, 2024 | WELLS, JAMES M | reporter.nih.gov |
| Mechanisms Regulating Neurotensin Secretion and Function | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,092,161 | February 1, 2017 | June 30, 2026 | EVERS, BERNARD MARK | reporter.nih.gov |
| Mechanisms of Altered Hepatic Transport: Impact on Drug Therapy | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,067,940 | April 5, 2017 | March 31, 2027 | BROUWER, KIM L.R. | reporter.nih.gov |
| LIVOPT -- LIVer cirrhosis - Optimizing Prediction of Patient OuTcomes | NIH | National Institute on Aging | 2021 to 2025 | $3,057,044 | September 30, 2021 | May 31, 2027 | LADNER, DANIELA P | reporter.nih.gov |
| RNA modifications in apolipoprotein regulation by environmental exposures | NIH | National Institute of Environmental Health Sciences | 2025 | $3,051,769 | September 11, 2025 | August 31, 2029 | KLINGE, CAROLYN M. | reporter.nih.gov |
| Bile acid composition and insulin sensitivity | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,050,866 | September 15, 2017 | August 31, 2027 | HAEUSLER, REBECCA ANNE | reporter.nih.gov |
| The Impact of HCV Treatment in HIV/HCV coinfected and HCV monoinfected Incarcerated Persons on HCV Elimination | NIH | National Institute on Drug Abuse | 2021 to 2024 | $3,045,888 | September 30, 2020 | August 31, 2025 | IRVIN, RISHA | reporter.nih.gov |
| GMP MANUFACTURE OF CLINICAL GRADE THERAPEUTIC VACCINE FOR THE TREATMENT OF PATIENTS WITH CHRONIC HBV | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $3,034,670 | June 5, 2018 | March 31, 2025 | NAKAAR, VALERIAN | reporter.nih.gov |
| Dissecting the pathogenesis and outcomes of PSC using multi-omics by studying the exposome and genome | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $3,027,125 | September 1, 2018 | July 31, 2025 | LAZARIDIS, KONSTANTINOS N | reporter.nih.gov |
| A Randomized Trial to Test the Efficacy of a Partner Navigation Intervention for HCV Treatment among Young Adult People who Inject Drugs | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,017,588 | June 1, 2022 | March 31, 2027 | MORRIS, MEGHAN D | reporter.nih.gov |
| Analysis of Chemical Structures and Therapeutic Activity of Agents for HIV, TB, and HBV (CHEMDB) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,016,918 | September 30, 2024 | September 29, 2025 | SUMNER, LOUISE | reporter.nih.gov |
| HAWAII CLINICAL RESEARCH NETWORK FOR HEALTH EQUITY | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2023 | $3,015,250 | September 24, 2022 | June 30, 2024 | SHIKUMA, CECILIA M. | reporter.nih.gov |
| Multi-level Evaluation of Racial/ethnic Disparities in Liver Disease Outcomes | NIH | National Cancer Institute | 2021 to 2025 | $3,010,755 | March 18, 2021 | February 28, 2027 | KANWAL, FASIHA | reporter.nih.gov |
| Generating Exogenic Organs for Transplantation without the Use of Immunosuppression | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,005,890 | September 21, 2022 | July 31, 2027 | STEER, CLIFFORD JOHN | reporter.nih.gov |
| Harnessing human brain and liver microphysiological systems for testing therapeutics for metastatic melanoma | NIH | National Center for Advancing Translational Sciences | 2021 to 2022 | $3,003,024 | August 1, 2018 | July 31, 2024 | WIKSWO, JOHN PETER | reporter.nih.gov |
| Mechanisms of T Cell Quiescence and Exhaustion | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,001,713 | March 1, 2019 | February 28, 2029 | SARKAR, SUROJIT | reporter.nih.gov |
| Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,000,000 | May 24, 2021 | April 30, 2025 | COBURN, GLEN ANDREW | reporter.nih.gov |
| Regulation of mitochondrial health in mammalian livers. | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $2,999,512 | September 1, 2025 | August 31, 2029 | MISHRA, PRASHANT | reporter.nih.gov |
| A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,998,001 | April 21, 2020 | March 31, 2027 | SIM, B. KIM LEE | reporter.nih.gov |
| Targeting hepatitis B virus cccDNA during HBV/HIV co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,993,820 | August 20, 2024 | July 31, 2029 | PLOSS, ALEXANDER | reporter.nih.gov |
| Regulation of PDAC metabolism and immunity by collagen and its cleavage products | NIH | National Cancer Institute | 2022 to 2025 | $2,987,434 | September 21, 2022 | August 31, 2025 | KARIN, MICHAEL | reporter.nih.gov |
| A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients | NIH | National Cancer Institute | 2021 to 2025 | $2,980,235 | April 1, 2021 | March 31, 2027 | KASEB, AHMED | reporter.nih.gov |
| Molecular Magnetic Resonance of Hepatic Fibrogenesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,974,604 | July 3, 2019 | March 31, 2028 | CARAVAN, PETER D | reporter.nih.gov |
| Translational control underlies nutrition and metabolism in health and disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $2,971,227 | September 4, 2025 | August 31, 2029 | RUGGERO, DAVIDE | reporter.nih.gov |
| Discordant transcriptional regulation of gluconeogenic and lipogenic gene expression | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,971,019 | June 15, 2016 | June 30, 2026 | PESSIN, JEFFREY E. | reporter.nih.gov |
| Photoabsorbing bioinks for expanding 3D printed human liver in situ | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,967,973 | September 21, 2021 | May 31, 2026 | STEVENS, KELLY R | reporter.nih.gov |
| Human on a chip systems to investigate disease comorbidities common in the aged population | NIH | National Institute on Aging | 2021 to 2022 | $2,967,932 | April 1, 2018 | April 30, 2025 | SHULER, MICHAEL L | reporter.nih.gov |
| Anchimerically Activatable Anti-Zika/Dengue ProTides | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,946,770 | August 1, 2021 | July 31, 2026 | WAGNER, CARSTON R. | reporter.nih.gov |
| Consortium on Translational Research in Early Detection of Liver Cancer:Data Management and Coordinating Center (DMCC) | NIH | National Cancer Institute | 2021 to 2025 | $2,944,568 | September 17, 2018 | August 31, 2028 | FENG, ZIDING | reporter.nih.gov |
| Ethanol Effects on the Transcriptional Regulatory Network in Liver Regeneration | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,943,903 | September 30, 2009 | July 31, 2027 | SRIVASTAVA, ANKITA | reporter.nih.gov |
| Exosomes and the Immune Response in Allograft Outcomes in Pediatric Transplant Recipients | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,938,841 | May 10, 2022 | June 30, 2024 | KRAMS, SHERI M. | reporter.nih.gov |
| Novel IL-23 inhibitor for the treatment of alcohol associated liver disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $2,935,798 | September 20, 2020 | August 31, 2025 | LOOMBA, ROHIT | reporter.nih.gov |
| Role and mechanisms of excretion in manganese neurotoxicity | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $2,931,400 | July 3, 2020 | June 30, 2027 | MUKHOPADHYAY, SOMSHUVRA | reporter.nih.gov |
| Moderately CHO-restricted diet as treatment targeting improvement in hepatic lipid and insulin sensitivity in adolescents with NAFLD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,928,802 | May 5, 2021 | July 31, 2026 | GOSS, AMY MISKIMON | reporter.nih.gov |
| Dynamic Strategies for the clinical management of HIV disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,926,858 | August 9, 2012 | May 31, 2028 | HERNAN, MIGUEL | reporter.nih.gov |
| Quantitative Multimodal Imaging Biomarkers for Combined Locoregional and Immunotherapy of Liver Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,920,314 | August 1, 2016 | August 31, 2027 | DUNCAN, JAMES S | reporter.nih.gov |
| PNPLA3 in Susceptibility and Resistance to Fatty Liver Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,920,007 | August 1, 2011 | July 31, 2027 | HOBBS, HELEN HASKELL | reporter.nih.gov |
| In utero gene editing to cure a metabolic liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,918,864 | February 1, 2020 | January 31, 2026 | PERANTEAU, WILLIAM H. | reporter.nih.gov |
| Innate Immune Mechanisms Contributing to Cancer Growth in Obesity | NIH | National Cancer Institute | 2021 to 2025 | $2,914,829 | July 1, 2021 | June 30, 2026 | ENGLEMAN, EDGAR G. | reporter.nih.gov |
| High subzero preservation of liver for transplantation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,898,028 | July 17, 2017 | December 31, 2025 | TONER, MEHMET | reporter.nih.gov |
| Roles of Neogenin and Matriptase-2 in Iron Homeostasis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,896,213 | February 1, 2015 | July 31, 2028 | ZHANG, AN-SHENG | reporter.nih.gov |
| Kinetic and structural basis for SARS-CoV-2 RNA-dependent RNA polymerase specificity and inhibition | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,889,190 | July 16, 2021 | June 30, 2027 | JOHNSON, KENNETH ALLEN | reporter.nih.gov |
| Genetic Repair of Familial Hypercholesterolemia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,883,128 | December 20, 2016 | March 31, 2027 | LAGOR, WILLIAM RAYMOND | reporter.nih.gov |
| Non-invasive etiology-adjusted precision liver cancer risk prediction | NIH | National Cancer Institute | 2025 | $2,876,456 | August 5, 2025 | July 31, 2029 | HOSHIDA, YUJIN | reporter.nih.gov |
| Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis Network | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,869,940 | September 23, 2021 | July 31, 2027 | BROWN, ROBERT S | reporter.nih.gov |
| A Testing Program to Identify Novel Agents for Treatment of Pediatric and AYA High-Risk Sarcoma, Kidney and Liver Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,862,121 | September 1, 2021 | June 30, 2026 | KURMASHEVA, RAUSHAN | reporter.nih.gov |
| Phenotyping Genetic Disorders of Hepatic Lipid and Lipoprotein Metabolism in Cells, Mice, and Men | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,861,646 | January 1, 2017 | December 31, 2024 | GINSBERG, HENRY N | reporter.nih.gov |
| Cardiovascular Risk Reduction in an Aging HIV-Infected Population: The Impact of HCV Co-Infection | NIH | National Institute on Aging | 2021 to 2023 | $2,851,326 | May 1, 2019 | January 31, 2025 | TRIANT, VIRGINIA ATHENA | reporter.nih.gov |
| Clinical Resource for Alcoholic Hepatitis Inestigation | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,850,908 | August 1, 2016 | April 30, 2027 | SUN, ZHAOLI | reporter.nih.gov |
| Computational modeling for HCV vaccine trial design and optimal vaccine-based combination interventions | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,842,189 | November 1, 2021 | October 31, 2026 | DAHARI, HAREL | reporter.nih.gov |
| Cooperative mechanisms of HIV-enhanced liver fibrogenesis in HBV Coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,836,440 | July 15, 2020 | June 30, 2027 | CHUNG, RAYMOND T | reporter.nih.gov |
| Neoantigen-specific T cell responses for Fibrolamellar Hepatocellular Carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $2,835,203 | May 1, 2022 | April 30, 2027 | YARCHOAN, MARK | reporter.nih.gov |
| Expression, Regulation and Function of the SULT1C Carcinogen-Activating Enzymes | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $2,833,481 | January 8, 2014 | December 31, 2026 | RUNGE-MORRIS, MELISSA A | reporter.nih.gov |
| Significance and mechanisms of hepatic ChREBPα induction via post-translational modifications in diet-induced NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,830,469 | April 1, 2014 | May 31, 2027 | YIN, LEI | reporter.nih.gov |
| Investigating Syndecan-1 in Hepcidin Regulation and Iron Metabolism | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,828,600 | February 1, 2021 | April 9, 2026 | GORDTS, PHILIP | reporter.nih.gov |
| Data-Driven Mathematical and Computational Modeling of Hepatitis D Infection and Treatment Response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,802,377 | February 15, 2020 | January 31, 2026 | DAHARI, HAREL | reporter.nih.gov |
| Improving Medication Adherence in adolescents who had a Liver Transplant: iMALT | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $2,801,000 | September 20, 2018 | August 31, 2025 | SHEMESH, EYAL | reporter.nih.gov |
| Hepatic gene transfer for the treatment of hemophilia B and other genetic diseases | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,797,035 | September 1, 2000 | December 31, 2027 | KAY, MARK A | reporter.nih.gov |
| Selective mTORC1 inhibition to prevent and treat NAFLD and NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,795,850 | July 15, 2016 | May 31, 2026 | ARANY, ZOLTAN P | reporter.nih.gov |
| Cognitive Function, Self-Management, and Health Outcomes among Liver Transplant Recipients: the LivCog Cohort | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,788,955 | May 4, 2022 | February 28, 2027 | SERPER, MARINA | reporter.nih.gov |
| Academic-Industrial Partnership to Develop Clinical Tools for Algorithmic Irreversible Electroporation of Inoperable Tumors | NIH | National Cancer Institute | 2022 to 2025 | $2,782,634 | September 22, 2022 | August 31, 2027 | SANO, MICHAEL BENJAMIN | reporter.nih.gov |
| Metabolic Markers and Predictors of Childhood Obesity | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $2,780,011 | June 1, 1991 | February 28, 2026 | CAPRIO, SONIA | reporter.nih.gov |
| Novel Biomarkers for Post-Liver Transplant NASH Fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,777,764 | July 18, 2022 | May 31, 2027 | ARTEEL, GAVIN E | reporter.nih.gov |
| RNA modification in cardiometabolic disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,776,155 | August 1, 2021 | May 31, 2026 | SALLAM, TAMER | reporter.nih.gov |
| Statin Therapy for patients with compensated Cirrhosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,767,121 | September 22, 2021 | July 31, 2027 | TAPPER, ELLIOT | reporter.nih.gov |
| Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI | NIH | National Cancer Institute | 2021 to 2024 | $2,760,490 | September 7, 2020 | August 31, 2025 | KURHANEWICZ, JOHN | reporter.nih.gov |
| Multi-cancer early detection using cell-free DNA methylome analysis | NIH | National Cancer Institute | 2023 to 2025 | $2,757,500 | September 19, 2023 | August 31, 2028 | ZHOU, XIANGHONG JASMINE | reporter.nih.gov |
| Paneth cells-derived IL-17A and liver ischemia reperfusion injury | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,751,803 | July 1, 2021 | March 31, 2026 | LEE, H. THOMAS | reporter.nih.gov |
| Nuclear Receptor Control of T Cell Function in Discrete Intestinal Microenvironments | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,751,010 | September 23, 2021 | August 31, 2026 | SUNDRUD, MARK SCOTT | reporter.nih.gov |
| Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplant: The TEST Trial | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,750,911 | May 19, 2022 | April 30, 2027 | SERPER, MARINA | reporter.nih.gov |
| Metabolic impact of FGF-21 in adipose tissue and liver of PLWH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,750,246 | September 10, 2020 | June 30, 2026 | LAKE, JORDAN E | reporter.nih.gov |
| Defining mechanisms of extracellular succinate regulation over metabolic tissue function | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,748,905 | September 13, 2019 | June 30, 2028 | CHOUCHANI, EDWARD THOMAS | reporter.nih.gov |
| Gluconeogenesis and Glycogenolysis - Role and Regulation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,745,503 | June 1, 1978 | July 31, 2029 | EDGERTON, DALE S | reporter.nih.gov |
| Directing Tryptophan Immunometabolism to Ameliorate Liver Ischemic-Reperfusion Injury | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,744,402 | April 1, 2022 | December 31, 2025 | KESELOWSKY, BENJAMIN GEORGE | reporter.nih.gov |
| Determining how chronic ETOH influences the regenerative activities of hepatocyte subpopulations | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,741,497 | August 1, 2021 | April 30, 2026 | ZHU, HAO | reporter.nih.gov |
| AND-gated Synthetic Biomarkers for Early Detection of Liver Metastasis | NIH | National Cancer Institute | 2021 to 2025 | $2,734,586 | September 23, 2021 | August 31, 2027 | KWONG, GABRIEL A | reporter.nih.gov |
| Novel Targets for Reducing Atherosclerosis in Type 1 Diabetes | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,734,575 | December 1, 2021 | November 30, 2026 | BIDDINGER, SUDHA B | reporter.nih.gov |
| Association between pre-diagnosis hepatic fat infiltration and risk of liver metastasis and mortality in a large cohort of stage I-III colorectal cancer survivors | NIH | National Cancer Institute | 2022 to 2025 | $2,716,606 | September 23, 2022 | August 31, 2027 | GIOVANNUCCI, EDWARD | reporter.nih.gov |
| Targeting hepatic mitochondrial function in humans with NAFLD using insulin sensitizers | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,715,093 | April 15, 2022 | March 31, 2027 | NORTON, LUKE | reporter.nih.gov |
| Searching the blood metabolome to identify risk biomarkers for biliary tract cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,714,799 | May 1, 2022 | April 30, 2027 | SHU, XIAO-OU | reporter.nih.gov |
| Gene therapy for glycogen storage disease type III | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $2,697,948 | April 1, 2022 | March 31, 2027 | SUN, BAODONG | reporter.nih.gov |
| Covalent Chemistry on Nanosubstrates Enables Molecular Analysis of Purified Extracellular Vesicles in Hepatocellular Carcinoma | NIH | National Cancer Institute | 2021 to 2024 | $2,695,903 | July 7, 2020 | June 30, 2026 | TSENG, HSIAN-RONG | reporter.nih.gov |
| Integrative Polygenic Genetic Studies of Non-alcoholic Fatty Liver Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,693,501 | April 1, 2022 | March 31, 2027 | SPELIOTES, ELIZABETH K | reporter.nih.gov |
| Jagged-Notch signaling in NASH/fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,685,447 | February 15, 2019 | June 30, 2028 | PAJVANI, UTPAL | reporter.nih.gov |
| Advanced Fibrosis Detection and a Predictive Diagnostic Model for Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Primary Care | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $2,682,628 | September 1, 2025 | August 31, 2029 | SCHREINER, ANDREW DAVID | reporter.nih.gov |
| Defining the therapeutic efficacy, tolerogenic potential, and genotoxicity of liver-targeted AAV gene therapy for hemophilia A | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,682,494 | September 15, 2022 | June 30, 2027 | ALMEIDA-PORADA, GRACA DUARTE | reporter.nih.gov |
| Spinal cord injury causes liver pathology and metabolic dysfunction | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,668,295 | April 1, 2021 | March 31, 2027 | MCTIGUE, DANA M | reporter.nih.gov |
| Homeostatic Responses to Amino Acid Insufficiency | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,660,490 | September 20, 2016 | June 30, 2026 | ANTHONY, TRACY G. | reporter.nih.gov |
| Mechanisms of Advanced NAFLD Disparities in Hispanics: A Multi-level Analysis | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2025 | $2,655,656 | January 1, 2021 | November 30, 2026 | SETIAWAN, VERONICA WENDY | reporter.nih.gov |
| Hereditary Genetics of Hepatocellular Carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $2,655,540 | February 1, 2022 | June 30, 2027 | WANGENSTEEN, KIRK J | reporter.nih.gov |
| ER-mitochondrial communication in calcium signaling, energy metabolism and liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,653,887 | April 1, 2021 | January 31, 2027 | HAJNOCZKY, GYORGY | reporter.nih.gov |
| Deciphering the Mechanisms by which Long Chain Fatty Acid Oxidation Influences Spatial Microvesicular Steatosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $2,651,504 | September 5, 2025 | September 4, 2029 | HELSLEY, ROBERT NATHANIEL | reporter.nih.gov |
| Natural history, risk prediction and cost of cirrhosis in insured Americans. | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,651,386 | February 1, 2022 | May 31, 2026 | LADNER, DANIELA P | reporter.nih.gov |
| Lead optimization and target identification of drugs targeting hypnozoites | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,647,674 | August 7, 2020 | July 31, 2025 | KYLE, DENNIS E | reporter.nih.gov |
| Early Detection of Hepatocellular Carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $2,637,669 | June 3, 2016 | February 28, 2027 | BERETTA, LAURA | reporter.nih.gov |
| Discovery of novel therapeutic targets for NASH through deep phenotyping of human knockouts and mechanistic studies | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,636,860 | September 15, 2022 | June 30, 2026 | TABAS, IRA A | reporter.nih.gov |
| Identification and Characterization of Loci Associated with Non-alcoholic Fatty Liver Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,634,402 | April 1, 2021 | March 31, 2026 | ALLRED, NICHOLETTE D. | reporter.nih.gov |
| Altered Lipid Droplet Trafficking: Role in Alcoholic Fatty Liver Disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,633,095 | August 10, 2011 | June 30, 2027 | CASEY, CAROL A. | reporter.nih.gov |
| Coffee and metabolites modulating the gut microbiome for improved colorectal cancer survival | NIH | National Cancer Institute | 2022 to 2025 | $2,628,801 | June 2, 2022 | May 31, 2027 | SONG, MINGYANG | reporter.nih.gov |
| Triglycerides as a Predictor of Newborn Subcutaneous and Liver Fat: Contributors to Fetal Fat Accretion in Obese Pregnancies | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $2,620,225 | May 7, 2021 | March 31, 2027 | BARBOUR, LINDA ANNE | reporter.nih.gov |
| Control of iron absorption by intestinal HIF2 in iron and hematological disorders | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,618,906 | April 1, 2012 | December 31, 2026 | SHAH, YATRIK M | reporter.nih.gov |
| Cutaneous biomarkers of pediatric non-alcoholic fatty liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,615,502 | June 17, 2022 | March 31, 2027 | MOUZAKI, MARIALENA | reporter.nih.gov |
| Regulation of Metabolism by FGF21 | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,614,390 | July 15, 2015 | June 30, 2028 | POTTHOFF, MATTHEW JOSEPH | reporter.nih.gov |
| Racial and Ethnic Disparities in Hepatocellular Carcinoma Surveillance Among Patients with Cirrhosis Across Five Safety Net Organizations | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2025 | $2,613,442 | December 22, 2021 | November 30, 2026 | WONG, ROBERT JOHN | reporter.nih.gov |
| Systems Genetics Dissection of Non-alcoholic Steatohepatitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,612,818 | July 1, 2019 | March 31, 2028 | LUSIS, ALDONS JAKE | reporter.nih.gov |
| Recruitment for the efficacy trial of Tele-Harm Reduction in a federally qualified health center operated syringe services program | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,609,496 | May 1, 2021 | April 30, 2026 | TOOKES, HANSEL EMORY | reporter.nih.gov |
| Pathogenesis of Primary Biliary Cholangitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,607,525 | December 21, 2020 | November 30, 2025 | LAZARIDIS, KONSTANTINOS N | reporter.nih.gov |
| Harnessing macrophage lysosomal lipid metabolism in obesity-associated diseases | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,605,827 | July 4, 2022 | June 30, 2026 | SCHILLING, JOEL DAVID | reporter.nih.gov |
| The Comparative Effectiveness and Safety of Oral Anticoagulants in Patients with Cirrhosis and Atrial Fibrillation | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,604,074 | March 1, 2023 | February 29, 2028 | SIMON, TRACEY | reporter.nih.gov |
| Pre-IND Development of Polymeric Micelles with Dual Drug Payloads for HCC Therapy | NIH | National Cancer Institute | 2022 to 2025 | $2,603,837 | August 1, 2022 | June 30, 2027 | LI, CHUN | reporter.nih.gov |
| Glucagon secretion and action in humans | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,599,787 | September 25, 2017 | July 31, 2027 | VELLA, ADRIAN | reporter.nih.gov |
| Endovascular ChemoFilter to Reduce Doxorubicin Toxicity during Intra-Arterial Chemotherapy | NIH | National Cancer Institute | 2021 to 2024 | $2,599,664 | September 23, 2021 | August 31, 2025 | HETTS, STEVEN WILLIAM | reporter.nih.gov |
| Impact of the aging niche on cancer phenotypes probed using mouse cancer models produced by somatic engineering. | NIH | National Institute on Aging | 2021 to 2025 | $2,597,894 | September 30, 2021 | August 31, 2026 | LOWE, SCOTT W. | reporter.nih.gov |
| Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR) | NIH | National Cancer Institute | 2021 to 2024 | $2,581,284 | September 10, 2020 | August 31, 2025 | JARNAGIN, WILLIAM ROBERT | reporter.nih.gov |
| Statistical methods and designs for correlated outcome and covariate errors in studies of HIV/AIDS | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,561,527 | January 25, 2018 | January 31, 2028 | SHEPHERD, BRYAN EARL | reporter.nih.gov |
| BMP Ligands in Hepcidin Regulation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,560,949 | April 1, 2021 | January 31, 2026 | BABITT, JODIE L | reporter.nih.gov |
| Bio-Psycho-Social Drivers of Disparities in Liver Disease Progression among Korean Americans with Hepatitis B Infection | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,557,384 | April 12, 2021 | March 31, 2026 | JUON, HEE-SOON | reporter.nih.gov |
| Functions of vitamin E and the tocopherol transfer protein | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,551,370 | April 20, 2021 | December 31, 2025 | MANOR, DANNY | reporter.nih.gov |
| New Technologies for Real-Time MRI-Guided Robotic-Assisted Abdominal Interventions | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $2,544,474 | September 6, 2022 | June 30, 2027 | WU, HOLDEN H | reporter.nih.gov |
| Precise tumor targeting with logic CAR circuits | NIH | National Cancer Institute | 2021 to 2025 | $2,539,139 | September 17, 2021 | August 31, 2026 | WONG, WILSON | reporter.nih.gov |
| First-in-human study of a potent anti-HBsAg neutralizing antibody | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,534,231 | March 20, 2023 | February 28, 2027 | CASKEY, MARINA | reporter.nih.gov |
| Tumor-promoting and tumor-suppressive roles of Hepatic Stellate Cell Subpopulations in NASH-HCC | NIH | National Cancer Institute | 2021 to 2025 | $2,533,680 | July 20, 2021 | June 30, 2026 | SCHWABE, ROBERT F. | reporter.nih.gov |
| Mechanisms of Clinical and Hemodynamic Response to Pulmonary Vasodilator Therapy in Fontan physiology | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,530,672 | December 20, 2021 | November 30, 2026 | EGBE, ALEXANDER | reporter.nih.gov |
| Leveraging HCV Phylogenetic Networks to Prevent HIV and Other Blood Borne Infections Among People Who Inject Drugs | NIH | National Institute on Drug Abuse | 2021 | $2,520,000 | June 1, 2021 | May 31, 2026 | AKIYAMA, MATTHEW | reporter.nih.gov |
| ANALYSIS OF INTRAHEPATIC MACROPHAGE PROFILES FOR PREDICTING RISK OF FIBROSIS DEVELOPMENT IN PATIENTS WITH DIFFERENT TYPES OF CHRONIC LIVER DISEASE | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,517,485 | April 1, 2021 | March 31, 2027 | STEVENSON, HEATHER L | reporter.nih.gov |
| Design and characterization of bacterial population dynamics in solid tumor models | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2024 | $2,515,679 | August 1, 2021 | April 30, 2025 | HASTY, JEFF M | reporter.nih.gov |
| Role of antibodies in hepatitis E virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,508,951 | April 19, 2023 | March 31, 2028 | FENG, ZONGDI | reporter.nih.gov |
| Intestinally restricted LXR agonism in ameliorating liver failure in short gut syndrome | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,504,630 | March 1, 2019 | February 28, 2029 | RANDOLPH, GWENDALYN J | reporter.nih.gov |
| Role and regulation of beta-catenin in cholestatic liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,493,803 | July 1, 2015 | July 31, 2027 | NEJAK-BOWEN, KARI N | reporter.nih.gov |
| IL-15 and -21 armored GPC3-specific CAR T cells for children with solid tumors | NIH | National Cancer Institute | 2022 to 2025 | $2,490,304 | January 17, 2022 | October 31, 2025 | HECZEY, ANDRAS A. | reporter.nih.gov |
| Understanding human antibody responses to chronic viral hepatitis C | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,488,538 | January 17, 2022 | December 31, 2026 | LAW, MANSUN | reporter.nih.gov |
| Immune correlates of protection against hepacivirus persistence. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,486,556 | April 1, 2021 | September 30, 2025 | KAPOOR, AMIT | reporter.nih.gov |
| Radiation and dendritic cells to hepatomas to improve immunotherapy response | NIH | National Cancer Institute | 2022 to 2025 | $2,485,861 | September 1, 2022 | August 31, 2027 | PARK, SEAN S | reporter.nih.gov |
| TERT mRNA lipid nanoparticles to extend telomeres to treat alcoholic hepatitis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2024 | $2,484,849 | September 10, 2020 | August 31, 2025 | RAMUNAS, JOHN | reporter.nih.gov |
| The role of AEG-1 in NASH and NASH-HCC | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,484,379 | July 25, 2016 | December 31, 2025 | SARKAR, DEVANAND | reporter.nih.gov |
| High Resolution Ultrasound in Interventional Radiology | NIH | National Cancer Institute | 2022 to 2025 | $2,483,017 | March 4, 2022 | February 28, 2027 | FERRARA, KATHERINE W | reporter.nih.gov |
| Role of IRF3 in Energy and Glucose Homeostasis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,482,473 | April 1, 2015 | August 31, 2025 | ROSEN, EVAN D | reporter.nih.gov |
| Quantification of Liver Fibrosis with MRI and Deep Learning | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2024 | $2,480,232 | April 1, 2021 | December 31, 2025 | HE, LILI | reporter.nih.gov |
| Leveraging Novel Randomized Clinical Trials of Vitamin D Supplementation in Patients with Colorectal Cancer: Impact on Survival and Anti-Tumor Immunity | NIH | National Cancer Institute | 2021 to 2025 | $2,477,583 | March 15, 2017 | June 30, 2027 | NG, KIMMIE | reporter.nih.gov |
| HBV Capsid Effectors | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,475,992 | June 1, 2017 | February 28, 2027 | SCHINAZI, RAYMOND FELIX | reporter.nih.gov |
| The role of TLRs, Type II IFN and Type III IFN in a Murine Model of Autoinflammation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,474,645 | March 19, 2021 | February 28, 2026 | MARSHAK-ROTHSTEIN, ANN | reporter.nih.gov |
| Multidisciplinary Training in Translational Gastrointestinal and Liver Research | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,458,842 | July 1, 2009 | June 30, 2029 | WANG, TIMOTHY CRAGIN | reporter.nih.gov |
| Preservation of DCD Allograft Integrity for Liver Transplantation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,457,892 | January 13, 2020 | November 30, 2025 | BLACK, SYLVESTER M | reporter.nih.gov |
| Impairment of anti-Plasmodium T cell memory by type I Interferon Signaling | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,456,734 | June 1, 2023 | May 31, 2028 | MINKAH, NANA KWAKU | reporter.nih.gov |
| SPATIALLY MAPPING OF POOLED IN VIVO CRISPR SCREENS IN THE TUMOR MICROENVIRONMENT | NIH | National Cancer Institute | 2022 to 2025 | $2,452,762 | September 26, 2022 | August 31, 2027 | GAUBLOMME, JELLERT | reporter.nih.gov |
| Molecular Magnetic Resonance Imaging of Inflammation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,451,935 | August 1, 2019 | November 30, 2029 | GALE, ERIC MICHAEL | reporter.nih.gov |
| Sex-Specific Risk of Metabolic and Cardiovascular Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,450,619 | June 15, 2019 | June 30, 2025 | STAFFORD, JOHN MICHAEL | reporter.nih.gov |
| Alpha-Particle Emitter Radiopharmaceutical Therapy for Liver Cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,446,660 | December 1, 2019 | November 30, 2024 | NEDROW, JESSIE | reporter.nih.gov |
| Dissecting the Role of Arachidonic Acid Metabolic Pathways Involved in Resolution Versus Progression of PM-Induced Cardiometabolic Toxicity | NIH | National Institute of Environmental Health Sciences | 2022 to 2025 | $2,445,294 | February 11, 2022 | November 30, 2026 | ARAUJO, JESUS ANTONIO | reporter.nih.gov |
| New generation of long acting nucleos(t)ides and immune stimulant for treatment of chronic hepatitis B | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,444,033 | March 10, 2022 | February 28, 2027 | OSNA, NATALIA ALEKSANDR | reporter.nih.gov |
| Fully Automated High-Throughput Quantitative MRI of the Liver | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $2,442,717 | April 8, 2022 | December 31, 2026 | REEDER, SCOTT B. | reporter.nih.gov |
| Digital, Community-Led, Social Action Initiative to Reduce Opioid Vulnerability and HIV/HCV in Rural Areas of the Midwest and Appalachia | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,437,500 | May 1, 2019 | April 30, 2025 | ALBARRACIN, DOLORES | reporter.nih.gov |
| A binational cohort of the intersection between substance use, HIV, and associated comorbidities among people who inject drugs in San Diego, CA | NIH | National Institute on Drug Abuse | 2025 | $2,437,310 | July 15, 2025 | May 31, 2030 | STRATHDEE, STEFFANIE A. | reporter.nih.gov |
| Blocking hepatocyte senescence as a novel therapeutic strategy for chronic liver diseases | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,436,055 | September 30, 2021 | August 31, 2026 | OERTEL, MICHAEL | reporter.nih.gov |
| Integrative Physiology of Thyroid Hormone Receptors and Nuclear Receptor Corepressors | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,435,612 | June 1, 1991 | April 30, 2029 | LAZAR, MITCHELL A. | reporter.nih.gov |
| Continuation of the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Clinical Center-Cleveland site | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,432,868 | June 15, 2002 | June 30, 2027 | DASARATHY, SRINIVASAN | reporter.nih.gov |
| Colorado Center of Childhood Liver Disease ResearchNetwork | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,425,994 | September 15, 2002 | May 31, 2029 | SOKOL, RONALD J. | reporter.nih.gov |
| Developing Methods for Precise, Safe and Target-location Specific Histotripsy of Liver Tumors | NIH | National Cancer Institute | 2021 to 2025 | $2,424,900 | September 23, 2021 | August 31, 2026 | ZIEMLEWICZ, TIMOTHY J | reporter.nih.gov |
| Targeting tumor metabolism and immune environment via beta-catenin: Towards precision medicine in HCC | NIH | National Cancer Institute | 2021 to 2024 | $2,424,874 | August 1, 2020 | April 30, 2026 | MONGA, SATDARSHAN SINGH | reporter.nih.gov |
| YAP signaling in the pathogenesis of NAFLD in people living with HIV | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,422,019 | September 26, 2023 | July 31, 2028 | CHUNG, RAYMOND T | reporter.nih.gov |
| Novel therapies that target mitochondrial dysfunction for treatment of a1-antitrypsin deficiency liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,419,386 | December 16, 2021 | November 30, 2026 | RUDNICK, DAVID A | reporter.nih.gov |
| Mapping MTP lipid transfer activities for better therapeutics | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,418,719 | April 1, 2021 | March 31, 2026 | HUSSAIN, M MAHMOOD | reporter.nih.gov |
| Molecular Prosthetics and Lego Chemistry | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $2,415,883 | June 1, 2016 | February 29, 2028 | BURKE, MARTIN D | reporter.nih.gov |
| eXtended Modular ANthropomorphic (XMAN) phantom for Imaging and Treatment Optimization in Radiotherapy. | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $2,413,945 | September 1, 2022 | May 31, 2027 | REN, LEI | reporter.nih.gov |
| The Role of Portal Fibroblasts in Cholestatic Liver Fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,413,733 | September 15, 2014 | March 31, 2027 | KISSELEVA, TATIANA | reporter.nih.gov |
| A novel paradigm of sensitization of the tumor microenvironment with image-guided ultrasound cavitation and mechanotherapeutics for targeted HCC treatment | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $2,413,221 | August 15, 2022 | May 31, 2027 | AVERKIOU, MICHALAKIS | reporter.nih.gov |
| ATP Binding Cassette Transporters in Health and Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,408,231 | April 9, 2021 | January 31, 2025 | TARLING, ELIZABETH JOANNA | reporter.nih.gov |
| Biopsy Tract Sealing Device with Magnetic Resonance and X-Ray Image Contrast | NIH | National Cancer Institute | 2021 to 2024 | $2,408,201 | February 15, 2021 | January 31, 2026 | MAITLAND, DUNCAN J | reporter.nih.gov |
| Defining the role of the RNA modification N6-methyladenosine during Flaviviridae virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,403,276 | June 1, 2016 | January 31, 2027 | HORNER, STACY MICHELLE | reporter.nih.gov |
| Atlanta Center for the Childhood Liver Disease Research Network (ChiLDReN) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $2,403,001 | March 7, 2005 | May 31, 2024 | KARPEN, SAUL J. | reporter.nih.gov |
| Longitudinal integration of environmental exposures, omics, and childhood NAFLD (LEON) Study | NIH | National Human Genome Research Institute | 2023 to 2025 | $2,401,345 | September 12, 2023 | May 31, 2028 | CHATZI, VAIA LIDA | reporter.nih.gov |
| Development of polymeric synthetic biomaterial IP-001 to potentiate asystemic immunotherapy of hepatocellular carcinoma via thermal ablation | NIH | National Cancer Institute | 2021 to 2024 | $2,400,000 | August 16, 2021 | August 31, 2025 | LAM, SIU KIT | reporter.nih.gov |
| Development of heparan sulfate-based therapeutics to treat inflammatory diseases | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $2,387,583 | September 14, 2021 | July 31, 2026 | WANG, ZHANGJIE | reporter.nih.gov |
| Biomarkers of Alcoholic Hepatitis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $2,386,096 | June 1, 2020 | May 31, 2026 | ARTEEL, GAVIN E | reporter.nih.gov |
| The mTOR-ETV5 signaling in gastric X/A like cells and its role in hepatic lipid metabolism and steatosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,377,177 | July 1, 2021 | March 31, 2026 | SEELEY, RANDY J | reporter.nih.gov |
| Lymphatics in the liver | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,371,957 | July 1, 2022 | June 30, 2027 | IWAKIRI, YASUKO | reporter.nih.gov |
| The Role of the Intestinal Mycobiome in Alcoholic Liver Disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,368,040 | June 1, 2017 | March 31, 2027 | SCHNABL, BERND G. | reporter.nih.gov |
| Regulation and manipulation of the telomerase RNA component in hematopoiesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,367,468 | December 1, 2015 | May 14, 2026 | AGARWAL, SUNEET | reporter.nih.gov |
| Quantitative MRI and Deep Learning Technologies for Classification of NAFLD | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $2,364,000 | August 1, 2022 | April 30, 2027 | WU, HOLDEN H | reporter.nih.gov |
| Kentucky Outreach Service Kiosk (KyOSK): Reducing Overdose, Hepatitis C, and Other Drug-related Risks in Rural Appalachia through Health Kiosks | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,359,307 | August 15, 2022 | June 30, 2027 | YOUNG, APRIL MARIE | reporter.nih.gov |
| Parasite and host cell factors involved in the formation and persistence of Plasmodium vivax hypnozoites | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,358,624 | February 9, 2023 | January 31, 2028 | KAPPE, STEFAN HI | reporter.nih.gov |
| Molecular and cellular analysis of the ABHD5/PNPLA3 metabolon in lipid homeostasis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,358,124 | July 19, 2021 | June 30, 2027 | MOTTILLO, EMILIO | reporter.nih.gov |
| Engineering immunotherapeutic probiotics to mitigate irAE | NIH | National Cancer Institute | 2021 to 2024 | $2,351,179 | January 21, 2020 | December 31, 2024 | DANINO, TAL | reporter.nih.gov |
| Myeloid sphingolipid regulation of tissue resolution and regeneration responses | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,345,752 | September 21, 2022 | July 31, 2027 | HLA, TIMOTHY TUN | reporter.nih.gov |
| The NRF2-FBP1 crossregulatory loop and the control of healthy and diseased liver metabolism | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,345,542 | August 1, 2022 | November 30, 2025 | KARIN, MICHAEL | reporter.nih.gov |
| Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,342,707 | April 1, 2013 | April 30, 2026 | FORSBERG, FLEMMING | reporter.nih.gov |
| Disparities in the Diffusion of Direct-Acting Antiviral Therapy for Hepatitis C among Baby Boomers: A Mixed-Methods Study | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,331,243 | August 1, 2020 | June 30, 2025 | SHAPIRO, MARTIN F. | reporter.nih.gov |
| Heat shock protein 90 in alcoholic liver disease: targeting macrophage Function | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2025 | $2,330,377 | August 1, 2009 | June 30, 2027 | MANDREKAR, PRANOTI | reporter.nih.gov |
| Aldehydes in Alcohol-Induced Organ Injury | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,325,195 | September 30, 2010 | February 29, 2028 | ZHOU, ZHANXIANG | reporter.nih.gov |
| Adipsin in NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,324,625 | July 1, 2022 | April 30, 2027 | PAJVANI, UTPAL | reporter.nih.gov |
| Hepatocyte-derived extracellular vesicles in alcoholic liver disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $2,324,384 | July 1, 2020 | March 31, 2026 | FELDSTEIN, ARIEL | reporter.nih.gov |
| Ultrasound-mediated gene delivery to achieve therapeutic correction of hemophilia A | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,322,835 | April 1, 2020 | March 31, 2026 | MIAO, CAROL H | reporter.nih.gov |
| The role of IL-17 signaling in alcohol-induced HCC | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,322,600 | August 6, 2021 | May 31, 2027 | KISSELEVA, TATIANA | reporter.nih.gov |
| Regulation of hepatic uptake transporters by tyrosine kinases | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,321,588 | September 15, 2021 | August 31, 2026 | SPROWL, JASON A | reporter.nih.gov |
| Intestinal Resection Associated Liver Injury and Fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,314,904 | September 30, 2021 | August 31, 2025 | WARNER, BRAD WAYNE | reporter.nih.gov |
| Predicting outcomes in nonalcoholic steatohepatitis with advanced fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,310,512 | September 15, 2022 | June 30, 2027 | SANYAL, ARUN J | reporter.nih.gov |
| A vascularized patient-derived iPSC liver acinus microphysiology system as an innovative precision medicine platform for optimizing clinical trial design for nonalcoholic fatty liver disease | NIH | National Center for Advancing Translational Sciences | 2022 to 2024 | $2,306,928 | July 15, 2020 | June 30, 2026 | TAYLOR, D. LANSING | reporter.nih.gov |
| Investigation of the role of VEGFA in harnessing cholangiocyte-driven liver regeneration | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,306,170 | July 1, 2022 | April 30, 2027 | GOUON-EVANS, VALERIE B | reporter.nih.gov |
| Fecal microbiota transplant for Alcohol-Associated Cirrhosis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2025 | $2,300,878 | September 12, 2022 | August 31, 2027 | BAJAJ, JASMOHAN S | reporter.nih.gov |
| TLC-1235, a controlled-release mitochondrial protonophore (CRMP), for the reversal of insulin resistance in patients with severe lipodystrophy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2024 | $2,299,997 | September 22, 2022 | August 31, 2025 | MYERS, ROBERT PAUL | reporter.nih.gov |
| Role of NgBR in regulating hepatic gluconeogenesis and insulin resistance | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,299,513 | April 1, 2022 | March 31, 2027 | MIAO, QING | reporter.nih.gov |
| DISSECTING THE LINK BETWEEN UREAGENESIS AND HEPATIC GLYCOGEN METABOLISM | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,297,784 | February 15, 2021 | January 31, 2027 | BURRAGE, LINDSAY C | reporter.nih.gov |
| Small molecule antagonists targeting EphB receptors for the treatment of nonalcoholic steatohepatitis (NASH) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,297,570 | August 1, 2021 | May 31, 2026 | MIMCHE, PATRICE | reporter.nih.gov |
| Maternal Obesity and Pediatric NAFLD: Fetal Origins and Long-term outcomes in Non Human Primates | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,294,587 | September 30, 2021 | July 31, 2025 | FRIEDMAN, JACOB E | reporter.nih.gov |
| Biology of REV-ERB nuclear receptors | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,293,818 | September 30, 1992 | June 30, 2025 | LAZAR, MITCHELL A. | reporter.nih.gov |
| Mitochondrial depolarization, mitophagy, and mitochondrial DAMPs in ALD | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,289,684 | August 1, 2018 | June 30, 2028 | ZHONG, ZHI | reporter.nih.gov |
| HuR/HIF – SIRT1 Signaling Axis in Liver Transplant Rejuvenation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,287,369 | April 1, 2003 | March 31, 2027 | KUPIEC-WEGLINSKI, JERZY W | reporter.nih.gov |
| Integrated analysis of HBV-specific CD4 T cell and B cell responses to define their role in chronic hepatitis B and HBV functional cure. | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,286,418 | July 1, 2024 | May 31, 2029 | LAUER, GEORG MICHAEL | reporter.nih.gov |
| PET Enabled Y-90 Microspheres for Radioembolization of Liver Tumors | NIH | National Cancer Institute | 2021 to 2022 | $2,286,178 | August 1, 2012 | July 31, 2024 | PENG, YONGREN BENJAMIN | reporter.nih.gov |
| Development and Validation of Prognostic Radiomic Markers of Response and Recurrence for Patients with Colorectal Liver Metastases | NIH | National Cancer Institute | 2021 to 2023 | $2,284,583 | March 1, 2019 | August 31, 2025 | DO, RICHARD KINH GIAN | reporter.nih.gov |
| Morning Meal-Associated Priming of the Liver | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,282,667 | September 24, 2021 | July 31, 2025 | CHERRINGTON, ALAN D | reporter.nih.gov |
| Rip Proteins in Innate Immune Signaling | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,272,136 | December 15, 2008 | August 31, 2025 | KELLIHER, MICHELLE ALICE | reporter.nih.gov |
| Diagnostic performance assessment and dose optimization using patient CT images: Application to deep-learning CT reconstruction and denoising technologies | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2025 | $2,270,801 | September 20, 2012 | December 31, 2027 | MCCOLLOUGH, CYNTHIA H | reporter.nih.gov |
| Evaluation of a persuasive health communication intervention designed to increase HIV/HCV screening among emergency departments patients who currently, formerly or never injected drugs | NIH | National Institute on Drug Abuse | 2022 to 2024 | $2,264,864 | September 30, 2022 | July 31, 2027 | MERCHANT, ROLAND C | reporter.nih.gov |
| Liver Xenotransplantation using CRISPR-modified Porcine Organs | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,264,625 | February 1, 2020 | December 1, 2023 | MARKMANN, JAMES FRANCIS | reporter.nih.gov |
| Understanding the role of stellate cells in the liver hematopoietic stem cell niche | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,262,921 | August 1, 2020 | July 31, 2025 | DING, LEI | reporter.nih.gov |
| Reverse-engineering precision liver cancer chemoprevention | NIH | National Cancer Institute | 2021 to 2023 | $2,262,334 | September 23, 2019 | August 31, 2025 | HOSHIDA, YUJIN | reporter.nih.gov |
| Phosphatidylinositol Metabolism and Trafficking in Atherosclerosis and Inflammation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,257,637 | April 1, 2020 | June 30, 2028 | GULSHAN, KAILASH | reporter.nih.gov |
| Intermountain West Clinical Center for a Childhood Liver Disease Research Network | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,255,217 | August 20, 2014 | May 31, 2029 | GUTHERY, STEPHEN L | reporter.nih.gov |
| HDAC1 as a nutrient sensor in the development and progression of NAFLD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,254,125 | June 3, 2022 | March 31, 2027 | SHI, HANG | reporter.nih.gov |
| Deciphering and targeting a non-genetic driver pathway in hepatocellular carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $2,252,988 | February 12, 2021 | January 31, 2026 | WAJAPEYEE, NARENDRA | reporter.nih.gov |
| Novel alveolar mechanisms of hypoxemia in hepatopulmonary syndrome | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,251,770 | September 1, 2023 | June 30, 2027 | FALLON, MICHAEL B | reporter.nih.gov |
| Phosphodiesterase 4 mediated pathogenic mechanisms in alcohol associated liver disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,248,119 | September 22, 2021 | June 30, 2027 | GOBEJISHVILI, LEILA | reporter.nih.gov |
| Mechanisms of hepatitis B virus cccDNA formation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,246,607 | May 15, 2020 | April 30, 2025 | PLOSS, ALEXANDER | reporter.nih.gov |
| Control of Lipogenesis and Hepatic Steatosis by Caspase-2 | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,246,301 | March 15, 2019 | November 30, 2025 | KARIN, MICHAEL | reporter.nih.gov |
| Fibrogenesis Targeted Manganese Based MRI Contrast Agent | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2024 | $2,239,969 | September 15, 2022 | August 31, 2025 | HOFFMAN, VERA | reporter.nih.gov |
| Targeting Gq pathway in uveal melanoma | NIH | National Cancer Institute | 2022 to 2025 | $2,239,582 | September 7, 2022 | August 31, 2027 | CHEN, XU | reporter.nih.gov |
| Epigenetic Regulation of Mitochondrial Homeostasis and Energy Metabolism | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,238,787 | September 21, 2019 | June 30, 2027 | YANG, QIN | reporter.nih.gov |
| Dynamic Nuclear Polarization MR Spectroscopic Imaging for Diagnosis and Treatment Response Assessment in Hepatocellular Carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $2,238,522 | January 5, 2022 | December 31, 2026 | GADE, TERENCE P | reporter.nih.gov |
| Integrated Care for Addiction, HIV and HCV Research and Education (ICAHRE) | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,234,611 | July 1, 2017 | June 30, 2027 | STEIN, MICHAEL D | reporter.nih.gov |
| Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,229,932 | April 1, 2021 | December 31, 2025 | REEDER, SCOTT B. | reporter.nih.gov |
| Rural Comorbidity and HIV consequences of Opioid use Research and Treatment Initiative (Rural cohort) | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,227,803 | April 1, 2019 | March 31, 2026 | CRANE, HEIDI M. | reporter.nih.gov |
| New insights into the functional diversity of the hepatic antiviral T cell response during hepacivirus infection in vivo | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,227,294 | June 1, 2022 | May 31, 2027 | BILLERBECK, EVA | reporter.nih.gov |
| Novel Nanomedicine-Based Therapeutic Approach For Treatment of Cancer Cachexia | NIH | National Cancer Institute | 2021 to 2025 | $2,226,892 | May 1, 2024 | April 30, 2027 | TARATULA, OLEH | reporter.nih.gov |
| Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cure | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,223,594 | August 20, 2021 | June 30, 2027 | REMISZEWSKI, STACY | reporter.nih.gov |
| Novel mechanism based treatment to improve tissue injury in alcoholic hepatitis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $2,223,387 | September 25, 2020 | July 31, 2025 | DASARATHY, SRINIVASAN | reporter.nih.gov |
| Genetic Regulation of Nonalcoholic Fatty Liver Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,221,739 | June 8, 2021 | March 31, 2026 | MEDINA, MARISA WONG | reporter.nih.gov |
| Mechanisms of liver metastasis and associated resistance to immunotherapy | NIH | National Cancer Institute | 2021 to 2025 | $2,220,950 | March 9, 2021 | February 28, 2026 | IZAR, BENJAMIN | reporter.nih.gov |
| Targeting the gut-liver axis in cardiovascular disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,220,868 | December 15, 2022 | November 30, 2026 | VALLIM, THOMAS A | reporter.nih.gov |
| Role of Forkhead proteins in insulin action | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,219,659 | January 1, 2001 | July 31, 2025 | ACCILI, DOMENICO | reporter.nih.gov |
| Southern Liver Health Cohort | NIH | National Cancer Institute | 2021 to 2022 | $2,219,249 | September 21, 2021 | August 31, 2023 | HOYO, CATHRINE | reporter.nih.gov |
| Understanding the metabolic pathology of pediatric obesity and NAFLD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,218,267 | April 22, 2022 | January 31, 2027 | SHORT, KEVIN R. | reporter.nih.gov |
| Mechanistic function of HCV NS5A targeted by the potent inhibitors | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,218,100 | February 1, 2020 | January 31, 2026 | YI, MINKYUNG | reporter.nih.gov |
| Advancing 3D optical body surface scan technology to assess physiological and psychological effects in highly obese population | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,213,224 | September 1, 2021 | August 31, 2025 | HAHN, JAMES K | reporter.nih.gov |
| Investigating the role of frailty on outcomes in acutely ill patients with cirrhosis undergoing liver transplantation in the acute care setting | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,213,082 | July 15, 2023 | April 30, 2028 | LAI, JENNIFER C. | reporter.nih.gov |
| Mechanisms of Hepadnavirus Assembly and Replication | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,212,330 | February 15, 1999 | August 31, 2028 | HU, JIANMING | reporter.nih.gov |
| Systemic immunoregulatory consequences of bacterial translocation during health and disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,209,196 | September 21, 2021 | June 30, 2026 | MEISEL, MARLIES | reporter.nih.gov |
| The role of hepatocyte tPA in hepatic VLDL production. | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,208,015 | April 5, 2022 | March 31, 2027 | ZHENG, ZE | reporter.nih.gov |
| Gut region-specific mechanisms that limit dissemination of microbial signals from the intestine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,205,002 | September 8, 2021 | June 30, 2026 | RANDOLPH, GWENDALYN J | reporter.nih.gov |
| Role of TAZ in metabolic regulation in both normal and insulin resistant states | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,204,517 | December 10, 2020 | November 30, 2026 | MIAO, JI | reporter.nih.gov |
| Etiology of Persistent Microalbuminuria in Nigeria | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,202,068 | July 1, 2021 | May 31, 2026 | WESTER, C. WILLIAM | reporter.nih.gov |
| Ex-vivo bioengineered technology to unravel dysfunction due to non-alcoholic steatohepatitis (NASH) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,201,102 | July 1, 2023 | April 30, 2027 | WERTHEIM, JASON A | reporter.nih.gov |
| Estimating the population size of persons who inject drugs in New York | NIH | National Institute on Drug Abuse | 2021 to 2022 | $2,200,197 | June 1, 2021 | December 13, 2022 | BRADLEY, HEATHER | reporter.nih.gov |
| Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma | NIH | National Cancer Institute | 2021 to 2024 | $2,195,262 | December 1, 2019 | November 30, 2025 | SARKAR, DEVANAND | reporter.nih.gov |
| Role of heat shock transcription factor HSF1 in tumorigenesis | NIH | National Cancer Institute | 2021 to 2025 | $2,193,704 | July 1, 1996 | January 31, 2027 | MIVECHI, NAHID F | reporter.nih.gov |
| Insulin Regulation of Hepatic Function via Zone-Specific Transcriptional Programs | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,193,363 | May 1, 2021 | April 30, 2027 | BIDDINGER, SUDHA B | reporter.nih.gov |
| TCR signaling and cell cycle regulation in tumor-specific CD8 T cell dysfunction | NIH | National Cancer Institute | 2022 to 2025 | $2,191,917 | April 1, 2022 | March 31, 2027 | PHILIP, MARY | reporter.nih.gov |
| Acute Imposition of Fontan Physiology in The Single Ventricle Patient: Effects on Fibrosis, Function and Drug Intervention | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,190,858 | July 1, 2020 | June 30, 2026 | FOGEL, MARK A | reporter.nih.gov |
| HBV-specific T cell immunity in HBV/HIV coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,189,677 | August 1, 2025 | July 31, 2028 | VINIKOOR, MICHAEL JEFFREY | reporter.nih.gov |
| Sterile inflammation and pyroptotic cell death in liver fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,186,355 | March 1, 2017 | May 31, 2028 | HOFFMAN, HAROLD M | reporter.nih.gov |
| Regulation of Rhythmic m6A RNA Modification by ER‐associated Degradation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,185,865 | July 16, 2021 | December 31, 2025 | ZHANG, KEZHONG | reporter.nih.gov |
| RECK regulation of NASH and fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,185,559 | May 15, 2022 | April 30, 2027 | RECTOR, RANDY SCOTT | reporter.nih.gov |
| Advancing our Understanding of Rare Pediatric Liver Diseases | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,184,993 | September 15, 2002 | May 31, 2029 | LOOMES, KATHLEEN MARY | reporter.nih.gov |
| Deciphering Epithelial Signals in the Liver to Drive Inflammation and Fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,182,945 | July 1, 2021 | June 30, 2026 | YIMLAMAI, DEAN | reporter.nih.gov |
| Lipotoxicity and Liver Inflammation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,182,776 | April 15, 2020 | February 29, 2028 | IBRAHIM, SAMAR | reporter.nih.gov |
| Therapeutic Mitochondrial Uncouplers | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,181,641 | May 1, 2021 | December 31, 2025 | SANTOS, WEBSTER L | reporter.nih.gov |
| Multi-omics for obesity-associated liver disease in a high-risk population cohort | NIH | National Cancer Institute | 2023 to 2025 | $2,178,680 | September 1, 2023 | August 31, 2028 | MCCORMICK, JOSEPH | reporter.nih.gov |
| Understanding the Multilevel Drivers of Liver Cancer Disparities | NIH | National Cancer Institute | 2021 to 2023 | $2,174,412 | August 16, 2019 | July 31, 2025 | SHARIFF-MARCO, SALMA | reporter.nih.gov |
| Integrative Liver Cell Core | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,169,055 | June 15, 2001 | May 31, 2027 | TSUKAMOTO, HIDEKAZU | reporter.nih.gov |
| Regulation of tumor-infiltrating T cells by macrophages | NIH | National Cancer Institute | 2021 to 2025 | $2,167,459 | June 15, 2021 | May 31, 2027 | HUANG, XIAOPEI | reporter.nih.gov |
| Impaired VLDL secretion in progression of NAFLD and NASH in mice and humans | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,167,149 | July 16, 2019 | June 30, 2028 | DAVIDSON, NICHOLAS O. | reporter.nih.gov |
| Exosomal biomarkers for the early detection of hepatocellular carcinoma | NIH | National Cancer Institute | 2023 to 2025 | $2,166,339 | August 8, 2023 | July 31, 2028 | GOEL, AJAY | reporter.nih.gov |
| MicroRNAs in Alcoholic Liver Disease Administrative Supplement | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2023 | $2,165,347 | September 10, 2011 | July 31, 2024 | SZABO, GYONGYI | reporter.nih.gov |
| Mechanisms of gallbladder smooth muscle dysfunction | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,161,620 | July 18, 2022 | May 31, 2027 | LAVOIE, BRIGITTE | reporter.nih.gov |
| Unlocking the Chemical Space of Cancer-Associated Perturbations | NIH | National Cancer Institute | 2022 to 2025 | $2,158,944 | September 14, 2022 | August 31, 2027 | BRADY, DONITA C | reporter.nih.gov |
| Long-Acting, Short-Residing Nanochelators for Iron Overload Therapy | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,154,309 | January 1, 2023 | December 31, 2026 | CHOI, HAK SOO | reporter.nih.gov |
| Dysregulated neutrophil subpopulations as a driving mechanism of liver and gastrointestinal disease in HIV-1-infected individuals | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,145,951 | July 1, 2023 | April 30, 2028 | HEL, ZDENEK | reporter.nih.gov |
| Action of Lipolytic Enzymes | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,144,258 | January 1, 2021 | May 31, 2026 | DENNIS, EDWARD A | reporter.nih.gov |
| Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $2,139,998 | September 11, 2017 | August 31, 2024 | BLITZER, JEREMY | reporter.nih.gov |
| Integrated analysis of HCC CTCs for Liver Transplant Candidate Selection | NIH | National Cancer Institute | 2021 to 2024 | $2,139,039 | April 1, 2020 | March 31, 2026 | AGOPIAN, VATCHE | reporter.nih.gov |
| Novel roles of copper in adaptive responses to hypoxia | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,135,696 | September 30, 2021 | April 30, 2027 | PETRIS, MICHAEL J. | reporter.nih.gov |
| The Saint Louis University Component of the NASH Clinical Research Network | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,135,402 | May 20, 2002 | June 30, 2027 | NEUSCHWANDER-TETRI, BRENT A | reporter.nih.gov |
| Role of Wnt-Beta-catenin in liver development and metabolic zonation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,135,143 | January 1, 2004 | May 31, 2030 | MONGA, SATDARSHAN SINGH | reporter.nih.gov |
| Mechanisms of microcystin-induced hepatocellular carcinoma in nonalcoholic steatohepatitis | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $2,132,242 | January 19, 2021 | October 31, 2026 | CLARKE, JOHN DANIEL | reporter.nih.gov |
| A Role for the Novel HAF-NFkappaB Axis in Driving Obesity-Associated Liver Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,131,677 | September 1, 2025 | August 31, 2027 | KOH, MEI YEE | reporter.nih.gov |
| Uganda Schistosomiasis Multidisciplinary Research Centre (U-SMRC) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,130,877 | May 1, 2025 | April 30, 2027 | ELLIOTT, ALISON | reporter.nih.gov |
| Ketone Body Metabolism and Integrated Metabolic Homeostasis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,128,893 | August 5, 2011 | June 30, 2025 | CRAWFORD, PETER A | reporter.nih.gov |
| Innovative Genetic Approaches to Enhance Liver Repopulation and Reduce Cancer Risk and Progression | NIH | National Cancer Institute | 2021 to 2024 | $2,128,341 | July 15, 2020 | June 30, 2025 | KAESTNER, KLAUS H | reporter.nih.gov |
| Improving hepatocellular carcinoma mouse modeling by understanding the malignant potential and biology of liver cell subpopulations | NIH | National Cancer Institute | 2021 to 2024 | $2,123,250 | June 1, 2020 | May 31, 2025 | ZHU, HAO | reporter.nih.gov |
| A novel approach to treat non-alcoholic steatohepatitis (NASH) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $2,122,291 | June 1, 2021 | July 31, 2024 | ARBEENY, CYNTHIA | reporter.nih.gov |
| Them1-Mediated Metabolic Regulation and Pathogenic Role in MASLD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,121,350 | July 5, 2015 | June 30, 2029 | COHEN, DAVID E. | reporter.nih.gov |
| Structural mechanisms of Scap/SREBP signaling in membrane homeostasis | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,118,665 | April 1, 2020 | March 31, 2030 | ROSENBAUM, DANIEL | reporter.nih.gov |
| Multi-Omics Characterization of Plasmodium Vivax Hypnozoites | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,118,231 | December 22, 2022 | November 30, 2027 | SERRE, DAVID | reporter.nih.gov |
| Regulation of hepatic hepcidin expression by transferrin receptor-2 | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,117,351 | August 15, 2021 | July 31, 2025 | ENNS, CAROLINE | reporter.nih.gov |
| Toxic lipid intermediate accumulation and cobalamin depletion promote AHR-mediated hepatotoxicity and the progression of non-alcoholic fatty liver disease (NAFLD)-like pathologies | NIH | National Institute of Environmental Health Sciences | 2022 to 2025 | $2,117,038 | September 1, 2025 | August 31, 2027 | ZACHAREWSKI, TIMOTHY R. | reporter.nih.gov |
| Epidemiology of diet, metabolism and non-alcoholic fatty liver disease in Hispanic/Latino adults | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,113,449 | September 15, 2023 | July 31, 2027 | KAPLAN, ROBERT C | reporter.nih.gov |
| Microbiome and Intestinal Innate Immune Response in Alcoholic Liver Disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,112,911 | September 25, 2011 | June 30, 2026 | SCHNABL, BERND G. | reporter.nih.gov |
| Structural characterization of native HBV capsids and virions from human cells | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,112,197 | June 14, 2023 | May 31, 2028 | WANG, JOSEPH CHE-YEN | reporter.nih.gov |
| Pathophysiologic mechanisms leading to intrahepatic fat accumulation in obese youth | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2025 | $2,110,569 | April 21, 2021 | January 31, 2027 | SANTORO, NICOLA | reporter.nih.gov |
| Role of extracellular vesicles in the regulation of immunometabolism in obesity | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $2,103,955 | July 1, 2020 | June 30, 2024 | NAKAMURA, TAKAHISA | reporter.nih.gov |
| Role of Eosinophils in Hepatic Ischemia Reperfusion Injury | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,103,519 | June 1, 2019 | March 31, 2027 | JU, CYNTHIA | reporter.nih.gov |
| TLR5 enhancement of liver-directed radiotherapy plus immune checkpoint blockade against irradiated liver metastasis and abscopal tumors | NIH | National Cancer Institute | 2023 to 2025 | $2,103,321 | June 9, 2023 | May 31, 2028 | BRACKETT, CRAIG M. | reporter.nih.gov |
| Assessing performance of a Hepatitis C Emergency Department (HepC-END) Screening Tool | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,102,922 | September 15, 2023 | July 31, 2028 | PARK, HAESUK | reporter.nih.gov |
| Biological role and pharmacology of EXPERA family proteins and their effect onsterol homeostasis | NIH | National Institute of General Medical Sciences | 2025 | $2,102,917 | September 1, 2025 | August 31, 2029 | ALON, ASSAF | reporter.nih.gov |
| Thioesterase-mediated lipotoxicity in liver and thermogenic adipose tissue | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,101,800 | August 13, 2021 | April 30, 2027 | ERSOY, BARAN | reporter.nih.gov |
| A microsimulation of alcohol control interventions to advance health equity and reverse the current decrease in life expectancy in the US | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $2,099,693 | August 10, 2020 | July 31, 2026 | PROBST, CHARLOTTE | reporter.nih.gov |
| Imaging and Dosimetry of Yttrium-90 for Personalized Cancer Treatment | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2023 | $2,097,012 | September 15, 2016 | April 30, 2026 | DEWARAJA, YUNI K | reporter.nih.gov |
| A Telehealth Intervention to Increase Screening and Treatment for Alcohol Use Disorder | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2024 | $2,096,748 | September 20, 2022 | August 31, 2025 | MENDELSON, JOHN E. | reporter.nih.gov |
| Mini-Livers Derived from Human IPS Cells for Modeling Steatosis and Therapy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,096,374 | August 1, 2014 | May 31, 2025 | SOTO-GUTIERREZ, ALEJANDRO | reporter.nih.gov |
| Protective and fibrosis-independent functions of hepatic stellate cells | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,093,748 | April 1, 2021 | March 31, 2026 | SCHWABE, ROBERT F. | reporter.nih.gov |
| Mechanisms underlying hepatic immune cell recruitment in nonalcoholic fatty liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,092,488 | April 1, 2021 | March 31, 2027 | RAEMAN, REBEN | reporter.nih.gov |
| TNF alpha and Recovery from Alcoholic Liver Injury | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,088,463 | May 5, 2025 | April 30, 2030 | DIEHL, ANNA MAE ELIZABETH | reporter.nih.gov |
| Xenobiotic-responsive hepatic long non-coding RNAs | NIH | National Institute of Environmental Health Sciences | 2021 to 2024 | $2,078,339 | August 15, 2014 | April 30, 2026 | WAXMAN, DAVID J | reporter.nih.gov |
| Pathobiology of Liver Injury | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,077,361 | September 23, 2016 | August 31, 2026 | MALHI, HARMEET | reporter.nih.gov |
| Responding to the Increase in Substance Use, HIV, HCV, and Overdose in New England (RISE-NE) | NIH | National Institute on Drug Abuse | 2025 | $2,076,525 | August 15, 2025 | May 31, 2030 | BAZZI, ANGELA ROBERTSON | reporter.nih.gov |
| A Glucocorticoid Receptor-SETDB2 Co-Regulated Liver Metabolic Gene Program | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,076,141 | January 8, 2021 | December 31, 2025 | OSBORNE, TIMOTHY F | reporter.nih.gov |
| Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy | NIH | National Cancer Institute | 2021 to 2024 | $2,074,477 | July 1, 2020 | June 30, 2025 | NEL, ANDRE ELIAS | reporter.nih.gov |
| Defining a Role for Liver Myeloid Cells in Viral Persistence under ART | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,074,301 | July 1, 2022 | April 30, 2027 | STEVENSON, MARIO | reporter.nih.gov |
| Cholesterol toxicity in alcohol-associated hepatitis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2025 | $2,069,392 | May 15, 2023 | April 30, 2028 | JIANG, ZHENGHUI GORDON | reporter.nih.gov |
| Hepatic Steatosis Quantification with Ultrasound | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,068,831 | April 1, 2022 | March 31, 2027 | CHEN, SHIGAO | reporter.nih.gov |
| Role of alcohol adapted Kupffer cells in the progression and resolution of ALD | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,068,172 | September 27, 2000 | February 29, 2028 | WEINMAN, STEVEN A | reporter.nih.gov |
| Synergistic effects of ECM and heterotypic crosstalk on cellular responses in non-alcoholic fatty liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,068,034 | February 8, 2018 | June 30, 2027 | KHETANI, SALMAN R | reporter.nih.gov |
| A novel cholinergic circuitry in alcoholic liver disease (NIAAA) | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,066,485 | March 15, 2021 | January 31, 2027 | WU, JUN | reporter.nih.gov |
| Critical Lipid Species in the Hepatovirus Lifecycle | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,065,233 | December 12, 2019 | May 31, 2025 | LEMON, STANLEY M. | reporter.nih.gov |
| Epitope-Based CSP Vaccines Optimized to Achieve Long-Term Sterile Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,065,107 | August 23, 2023 | July 31, 2027 | MILICH, DAVID R. | reporter.nih.gov |
| Targeting the orphan nuclear receptor LRH-1 with small molecules | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,063,220 | July 1, 2017 | July 31, 2027 | ORTLUND, ERIC A | reporter.nih.gov |
| A novel pathway controls liver injury in NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,058,572 | June 23, 2022 | March 31, 2027 | ZHAO, PENG | reporter.nih.gov |
| Nonalcoholic Fatty Liver Disease (NAFLD) in Polycystic Ovary Syndrome: The Role of Androgens on Liver Injury and NAFLD Progression | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,051,810 | September 1, 2023 | June 30, 2028 | SARKAR, MONIKA | reporter.nih.gov |
| Arylsulfonamides for the Treatment of Primary and Metastatic Uveal Melanoma | NIH | National Cancer Institute | 2023 to 2024 | $2,050,000 | September 17, 2020 | March 31, 2026 | OFFERMANN, MARGARET KENNY | reporter.nih.gov |
| Genetic Viral and Host Adaptations to Breach Species Barriers of HCV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,049,912 | July 1, 2013 | December 31, 2028 | PLOSS, ALEXANDER | reporter.nih.gov |
| Optimizing small molecule SWELL1-LRRC8 modulators to treat Type 2 diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,048,193 | July 1, 2021 | April 30, 2027 | SAH, RAJAN | reporter.nih.gov |
| LIFR-alpha/JAK/STAT3-dependent Adipose Inflammation Contributes to Obesity-Associated NAFLD - Resubmissi | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,048,146 | January 1, 2022 | December 31, 2026 | INFANTE, RODNEY E | reporter.nih.gov |
| Functional identification of vagal sensory neurons innervating the liver | NIH | National Center for Complementary & Integrative Health | 2021 to 2025 | $2,045,665 | September 1, 2021 | August 31, 2026 | JO, YOUNG-HWAN | reporter.nih.gov |
| Delineating the molecular mechanisms of hepatocyte-to-cholangiocyte reprogramming | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,044,853 | April 1, 2022 | March 31, 2026 | SHIN, DONGHUN | reporter.nih.gov |
| Elimination of HCV and related liver disease among HIV-infected and -uninfected people who inject drugs | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,039,441 | January 15, 2019 | December 31, 2025 | THOMAS, DAVID L | reporter.nih.gov |
| QSM to Guide Iron Chelating Therapy in Transfusional Iron Overload | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $2,037,010 | February 1, 2019 | January 31, 2025 | WANG, YI | reporter.nih.gov |
| Evaluating risk factors for cirrhosis progression and response to statin therapy among a cohort of patients with cirrhosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,035,766 | September 22, 2021 | July 31, 2027 | GOLDBERG, DAVID SETH | reporter.nih.gov |
| Optimizing SWELL1 modulators to treat non-alcoholic steatohepatitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $2,035,065 | September 16, 2020 | August 31, 2025 | LERNER, DANIEL J | reporter.nih.gov |
| Factors Controlling Metabolic Flux in the Liver | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,034,463 | February 1, 2008 | February 28, 2027 | BURGESS, SHAWN C | reporter.nih.gov |
| Angiopoietin-2/Tie2 signaling regulation of liver metastasis in pancreatic neuroendocrine tumors | NIH | National Cancer Institute | 2022 to 2025 | $2,033,782 | July 12, 2022 | June 30, 2027 | KIM, MINAH | reporter.nih.gov |
| Liver-Gut-Microbiome Axis and Fatty acid absorption in Preterm Infants | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,033,411 | May 16, 2023 | February 29, 2028 | HAIR, AMY BORISKIE | reporter.nih.gov |
| Balance between HNF4a isoforms in the carbohydrate-lipid metabolic switch | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,026,304 | September 25, 2021 | July 31, 2027 | SLADEK, FRANCES M. | reporter.nih.gov |
| Continuous allocation score design for guaranteeing equity and reducing discards in kidney and liver transplantation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,022,974 | December 17, 2022 | November 30, 2027 | MASSIE, ALLAN B | reporter.nih.gov |
| The role of hypothalamic Slug in the regulation of leptin sensitivity, energy balance, and body weight | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,019,700 | August 1, 2017 | July 31, 2026 | RUI, LIANGYOU | reporter.nih.gov |
| Hepatic TGFbeta1 in Control of Type 2 Diabetes and NASH via FoxO1 Signaling | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,019,371 | December 1, 2021 | November 30, 2026 | GUO, SHAODONG | reporter.nih.gov |
| Roles of mechanotransduction in organ regeneration and fibrosis | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,017,930 | July 1, 2021 | April 30, 2027 | MENG, ZHIPENG | reporter.nih.gov |
| Development of caspase-6 inhibitors for treatment of NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,016,023 | January 1, 2023 | November 30, 2027 | SALTIEL, ALAN R. | reporter.nih.gov |
| Candidate selection of a LPAR1 antagonist for therapeutic application in NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2024 | $2,013,280 | September 20, 2021 | June 30, 2026 | TUCCI, FABIO COHEN | reporter.nih.gov |
| Microchip for HBV testing using HIV-infected blood samples | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,012,162 | February 6, 2023 | November 30, 2024 | SHAFIEE, HADI | reporter.nih.gov |
| Mechanisms of insulin resistance related to nonalcoholic steatohepatitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $2,007,393 | March 9, 2015 | March 31, 2025 | CZECH, MICHAEL P | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| University of California Los Angeles | Los Angeles, CA | 47 | $613.7 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 79 | $143.8 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 95 | $125.3 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 63 | $109.9 million | 0 | $0 |
| Yale University | New Haven, CT | 68 | $95 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 69 | $84.5 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 56 | $83.7 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 76 | $79.7 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 63 | $78.2 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 59 | $71.6 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 47 | $69.5 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 52 | $61.5 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 27 | $60.7 million | 0 | $0 |
| Duke University | Durham, NC | 36 | $59.9 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 50 | $57.2 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 14 | $51.1 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 37 | $46.5 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 19 | $46.2 million | 0 | $0 |
| Stanford University | Stanford, CA | 33 | $45.8 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 46 | $45.2 million | 0 | $0 |
| Washington University | Saint Louis, MO | 37 | $43.2 million | 0 | $0 |
| Children's Hosp of Philadelphia | Philadelphia, PA | 16 | $42.3 million | 0 | $0 |
| University of Washington | Seattle, WA | 32 | $42 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 32 | $41.8 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 23 | $41.3 million | 0 | $0 |
| Medical University of South Carolina | Charleston, SC | 25 | $39.6 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 42 | $39.4 million | 0 | $0 |
| University of Arizona | Tucson, AZ | 18 | $38.9 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 18 | $35.6 million | 0 | $0 |
| University of Louisville | Louisville, KY | 31 | $35.5 million | 0 | $0 |
| Emory University | Atlanta, GA | 42 | $33.1 million | 0 | $0 |
| University of Kansas Medical Center | Kansas City, KS | 28 | $32.1 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 17 | $30.8 million | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 14 | $29.2 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 27 | $29.1 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 21 | $28.3 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 20 | $28.3 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 25 | $27.7 million | 0 | $0 |
| University of Texas HLTH Science Center | San Antonio, TX | 14 | $27.5 million | 0 | $0 |
| Cleveland Clinic Lerner Com-Cwru | Cleveland, OH | 22 | $27 million | 0 | $0 |
| Virginia Commonwealth University | Richmond, VA | 26 | $26.2 million | 0 | $0 |
| University of Kentucky | Lexington, KY | 16 | $25.1 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 24 | $24.2 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 19 | $23.7 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 21 | $23.4 million | 0 | $0 |
| Cedars-Sinai Medical Center | Los Angeles, CA | 20 | $22.5 million | 0 | $0 |
| North Carolina State University | Raleigh, NC | 9 | $21.9 million | 0 | $0 |
| University of TX MD Anderson Can CTR | Houston, TX | 19 | $21.6 million | 0 | $0 |
| Wake Forest University Health Sciences | Winston-Salem, NC | 16 | $21.1 million | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 27 | $21.1 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 30 | $20.4 million | 0 | $0 |
| Thomas Jefferson University | Philadelphia, PA | 19 | $20.3 million | 0 | $0 |
| University of Hawaii | Honolulu, HI | 8 | $19.9 million | 0 | $0 |
| Beth Israel Deaconess Medical Center | Boston, MA | 19 | $19.3 million | 0 | $0 |
| University of Nebraska Medical Center | Omaha, NE | 22 | $19.2 million | 0 | $0 |
| University of Texas HLTH Sci CTR Houston | Houston, TX | 16 | $17.6 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 13 | $17.5 million | 0 | $0 |
| Rockefeller University | New York, NY | 14 | $17.4 million | 0 | $0 |
| Michigan State University | East Lansing, MI | 15 | $17.4 million | 0 | $0 |
| University of Oklahoma HLTH Sciences CTR | Oklahoma City, OK | 15 | $17.2 million | 0 | $0 |
| Research Inst Nationwide Children's Hosp | Columbus, OH | 17 | $16.9 million | 0 | $0 |
| Universitat Bern | Bern | 1 | $16.8 million | 0 | $0 |
| University of Florida | Gainesville, FL | 25 | $16.7 million | 0 | $0 |
| Lurie Children's Hospital of Chicago | Chicago, IL | 6 | $16.7 million | 0 | $0 |
| Scripps Research Institute, the | La Jolla, CA | 12 | $16.7 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 18 | $16.4 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 16 | $16.3 million | 0 | $0 |
| University of Missouri-Columbia | Columbia, MO | 10 | $16.1 million | 0 | $0 |
| University of Chicago | Chicago, IL | 16 | $16.1 million | 0 | $0 |
| Vanderbilt University | Nashville, TN | 13 | $15.2 million | 0 | $0 |
| Oklahoma Medical Research Foundation | Oklahoma City, OK | 1 | $15.2 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 18 | $15 million | 0 | $0 |
| Wayne State University | Detroit, MI | 11 | $14.3 million | 0 | $0 |
| Saint Louis University | Saint Louis, MO | 12 | $14.1 million | 0 | $0 |
| Ohio State University | Columbus, OH | 16 | $14 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 10 | $13.4 million | 0 | $0 |
| Loyola University Chicago | Maywood, IL | 11 | $13.4 million | 0 | $0 |
| Dana-Farber Cancer Inst | Boston, MA | 7 | $13.3 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 18 | $12.9 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 8 | $12.8 million | 0 | $0 |
| University of Illinois at Urbana-Champaign | Urbana, IL | 14 | $11.8 million | 0 | $0 |
| Louisiana State University | Baton Rouge, LA | 2 | $11.7 million | 0 | $0 |
| Harvard University D/b/a Harvard School of Public Health | Boston, MA | 8 | $11.6 million | 0 | $0 |
| Sloan-Kettering Inst Can Research | New York, NY | 12 | $11.5 million | 0 | $0 |
| University of California-Berkeley | Berkeley, CA | 9 | $11.4 million | 0 | $0 |
| University of Texas Med BR Galveston | Galveston, TX | 9 | $11.3 million | 0 | $0 |
| American Type Culture Collection | Manassas, VA | 1 | $10.7 million | 0 | $0 |
| Beckman Research Institute/city of Hope | Duarte, CA | 12 | $10.5 million | 0 | $0 |
| Georgia State University | Atlanta, GA | 7 | $10.2 million | 0 | $0 |
| Chiang Mai University | Chiang Mai | 1 | $10.1 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 9 | $10 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 8 | $9.8 million | 0 | $0 |
| University of California at Davis | Davis, CA | 14 | $9.8 million | 0 | $0 |
| Trustees of Boston University | Boston, MA | 6 | $9.2 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 9 | $8.9 million | 0 | $0 |
| University of Maryland, College Park | College Park, MD | 5 | $8.3 million | 0 | $0 |
| New York University D/b/a NYU Long Island School of Medicine | Mineola, NY | 5 | $8.3 million | 0 | $0 |
| Fundacao Oswaldo Cruz | Rio de Janeiro | 1 | $8.2 million | 0 | $0 |
| Sanaria, Inc. | Rockville, MD | 3 | $8 million | 0 | $0 |
| Texas A&m Agrilife Research | College Station, TX | 9 | $7.8 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 1,376 | $850,665,456 | 0 | $0 |
| 2024 | 1,460 | $794,612,392 | 0 | $0 |
| 2023 | 1,497 | $870,979,389 | 0 | $0 |
| 2022 | 1,501 | $884,499,118 | 0 | $0 |
| 2021 | 1,475 | $845,301,560 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.